SG10201708520YA - Bicyclic heterocycles as fgfr inhibitors - Google Patents

Bicyclic heterocycles as fgfr inhibitors

Info

Publication number
SG10201708520YA
SG10201708520YA SG10201708520YA SG10201708520YA SG10201708520YA SG 10201708520Y A SG10201708520Y A SG 10201708520YA SG 10201708520Y A SG10201708520Y A SG 10201708520YA SG 10201708520Y A SG10201708520Y A SG 10201708520YA SG 10201708520Y A SG10201708520Y A SG 10201708520YA
Authority
SG
Singapore
Prior art keywords
bicyclic heterocycles
fgfr inhibitors
fgfr
inhibitors
heterocycles
Prior art date
Application number
SG10201708520YA
Inventor
Yaping Sun
Liang Lu
Wenqing Yao
Jincong Zhuo
Liangxing Wu
Meizhong Xu
Ding-Quan Qian
Fenglei Zhang
Chunhong He
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of SG10201708520YA publication Critical patent/SG10201708520YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
SG10201708520YA 2013-04-19 2014-04-18 Bicyclic heterocycles as fgfr inhibitors SG10201708520YA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361813782P 2013-04-19 2013-04-19

Publications (1)

Publication Number Publication Date
SG10201708520YA true SG10201708520YA (en) 2017-12-28

Family

ID=50983108

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201708520YA SG10201708520YA (en) 2013-04-19 2014-04-18 Bicyclic heterocycles as fgfr inhibitors
SG11201508328PA SG11201508328PA (en) 2013-04-19 2014-04-18 Bicyclic heterocycles as fgfr inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201508328PA SG11201508328PA (en) 2013-04-19 2014-04-18 Bicyclic heterocycles as fgfr inhibitors

Country Status (35)

Country Link
US (5) US9533984B2 (en)
EP (2) EP2986610B9 (en)
JP (3) JP6449244B2 (en)
KR (2) KR102469849B1 (en)
CN (3) CN109776525B (en)
AR (1) AR096097A1 (en)
AU (3) AU2014253798C1 (en)
BR (1) BR112015026307B1 (en)
CA (2) CA3130452C (en)
CL (1) CL2015003089A1 (en)
CR (1) CR20150578A (en)
CY (1) CY1120556T1 (en)
DK (1) DK2986610T5 (en)
EA (2) EA035095B1 (en)
EC (1) ECSP15048555A (en)
ES (2) ES2893725T3 (en)
HK (2) HK1255159A1 (en)
HR (1) HRP20180365T2 (en)
HU (1) HUE036571T2 (en)
IL (2) IL241982B (en)
LT (1) LT2986610T (en)
ME (1) ME03015B (en)
MX (2) MX367878B (en)
MY (1) MY181497A (en)
NO (1) NO3087075T3 (en)
PE (1) PE20152033A1 (en)
PH (2) PH12015502383A1 (en)
PL (1) PL2986610T4 (en)
PT (1) PT2986610T (en)
RS (1) RS56924B9 (en)
SG (2) SG10201708520YA (en)
SI (1) SI2986610T1 (en)
TW (2) TWI715901B (en)
UA (1) UA120087C2 (en)
WO (1) WO2014172644A2 (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
PT3176170T (en) 2012-06-13 2019-02-05 Incyte Holdings Corp Substituted tricyclic compounds as fgfr inhibitors
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
SG10201708520YA (en) 2013-04-19 2017-12-28 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
RU2664118C2 (en) 2013-07-18 2018-08-15 Тайхо Фармасьютикал Ко., Лтд. Antitumor drug for intermittent administration of fgfr inhibitor
JP6084292B2 (en) 2013-07-18 2017-02-22 大鵬薬品工業株式会社 FGFR inhibitor resistant cancer therapeutics
PE20160546A1 (en) 2013-10-25 2016-05-26 Novartis Ag BICYCLE PYRIDYL DERIVED COMPOUNDS FUSED TO RING AS INHIBITORS OF FGFR4
ES2756748T3 (en) 2014-10-03 2020-04-27 Novartis Ag Use of fused ring bicyclic pyridyl derivatives as fgfr4 inhibitors
US20160115164A1 (en) * 2014-10-22 2016-04-28 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9694084B2 (en) 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
TWI712601B (en) 2015-02-20 2020-12-11 美商英塞特公司 Bicyclic heterocycles as fgfr inhibitors
MA41551A (en) 2015-02-20 2017-12-26 Incyte Corp BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
US9802917B2 (en) 2015-03-25 2017-10-31 Novartis Ag Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
KR101917557B1 (en) 2015-03-31 2018-11-09 다이호야쿠힌고교 가부시키가이샤 Determination of 3,5-substituted benzene alkynyl compound
EP3424505A4 (en) * 2016-03-04 2019-10-16 Taiho Pharmaceutical Co., Ltd. Preparation and composition for treatment of malignant tumors
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
WO2017202390A1 (en) * 2016-05-27 2017-11-30 杭州英创医药科技有限公司 Heterocyclic compound serving as fgfr4 inhibitor
CN107459519A (en) * 2016-06-06 2017-12-12 上海艾力斯医药科技有限公司 Annelated pyrimidines piperidines ring derivatives and its preparation method and application
KR102583737B1 (en) * 2017-03-03 2023-09-26 오클랜드 유니서비시즈 리미티드 FGFR Kinase Inhibitors and Pharmaceutical Uses
AR111960A1 (en) 2017-05-26 2019-09-04 Incyte Corp CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION
US10421765B2 (en) 2017-05-26 2019-09-24 Board Of Regents, The University Of Texas System Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinase
CN111867590B (en) 2017-07-13 2023-11-17 德州大学系统董事会 Heterocyclic inhibitors of ATR kinase
EP3765008B1 (en) 2018-03-16 2023-06-07 Board of Regents, The University of Texas System Heterocyclic inhibitors of atr kinase
WO2019181876A1 (en) 2018-03-19 2019-09-26 大鵬薬品工業株式会社 Pharmaceutical composition including sodium alkyl sulfate
US11466004B2 (en) 2018-05-04 2022-10-11 Incyte Corporation Solid forms of an FGFR inhibitor and processes for preparing the same
MA52493A (en) 2018-05-04 2021-03-10 Incyte Corp FGFR INHIBITOR SALTS
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CA3157361A1 (en) 2019-10-14 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
GB201915828D0 (en) * 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
BR112022010664A2 (en) 2019-12-04 2022-08-16 Incyte Corp DERIVATIVES OF A FGFR INHIBITOR
JP2023505258A (en) 2019-12-04 2023-02-08 インサイト・コーポレイション Tricyclic heterocycles as FGFR inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CA3169315A1 (en) * 2020-03-02 2021-09-10 The Johns Hopkins University Glucose triptolide conjugates and uses thereof
CN111960932B (en) * 2020-09-16 2022-11-08 沈阳药科大学 Dichlororesorcinol compound and preparation method and medical application thereof
WO2022221170A1 (en) 2021-04-12 2022-10-20 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
EP4352059A1 (en) 2021-06-09 2024-04-17 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
CN113527311B (en) * 2021-08-23 2022-05-06 中南大学湘雅医院 FGFR4 inhibitor, composition and application thereof in preparation of medicines
WO2023039828A1 (en) * 2021-09-17 2023-03-23 Nutshell Biotech (Shanghai) Co., Ltd. Fused ring compounds as inhibitors of fgfr4 tyrosine kinases
TW202320792A (en) 2021-11-22 2023-06-01 美商英塞特公司 Combination therapy comprising an fgfr inhibitor and a kras inhibitor

Family Cites Families (811)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE280853C (en)
US850370A (en) 1906-06-05 1907-04-16 William L Hynes Water-automobile.
DE2156720A1 (en) 1971-11-16 1973-05-24 Bayer Ag Pyrimido(4,5-d) pyrimidines - prepd from polychloroalkylimino acid chloride and 4-amino uracils, are starting materials for plant
US3894021A (en) 1974-01-28 1975-07-08 Squibb & Sons Inc Derivatives of 1,7-dihydro-2H-pyrazolo{8 4{40 ,3{40 :5,6{9 pyrido{8 4,3-D{9 pyrimidine-2,4-(3H)-diones
JPS5120580B2 (en) 1974-06-19 1976-06-25
JPS5120580A (en) 1974-08-08 1976-02-18 Nitto Electric Ind Co 4 futsukaechirenjugotaihifukudensenno seizohoho
US4347348A (en) 1978-06-05 1982-08-31 Chernikhov Alexei Y Heat-resistant heterocyclic polymers and methods for producing same
FR2428654A1 (en) 1978-06-13 1980-01-11 Chernikhov Alexei Heat-stable heterocyclic polymer prepn. - by reacting polyfunctional nitrile with polyfunctional isocyanate opt. contg. silicon, halogen, nitrogen, phosphorus and/or boron atoms
CH641470A5 (en) 1978-08-30 1984-02-29 Ciba Geigy Ag SILANES CONTAINING IMID GROUPS.
CH635828A5 (en) 1978-08-30 1983-04-29 Ciba Geigy Ag N-SUBSTITUTED IMIDES AND BISIMIDS.
US4339267A (en) 1980-01-18 1982-07-13 E. I. Du Pont De Nemours And Company Herbicidal sulfonamides
US4405519A (en) 1980-10-22 1983-09-20 Plastics Engineering Company Di-Acetylene-terminated polyimide derivatives
US4405786A (en) 1980-10-22 1983-09-20 Plastics Engineering Company Addition products of di-acetylene-terminated polyimide derivatives and an dienophile having ethylene groups
US4405520A (en) 1980-10-22 1983-09-20 Plastics Engineering Company Addition products of di-acetylene-terminated polymide derivatives and dienophiles having terminal maleimide grops
US4402878A (en) 1980-10-22 1983-09-06 Plastics Engineering Company Addition products of di-acetylene-terminated polyimide derivatives with a polyimide having terminal non-conjugated acetylene groups
JPS5857170A (en) 1981-09-30 1983-04-05 シャープ株式会社 Study apparatus
JPS5873576U (en) 1981-11-12 1983-05-18 沖電気工業株式会社 Connector lock structure
US4460773A (en) 1982-02-05 1984-07-17 Lion Corporation 1-Phenyl-1H-pyrazolo [3,4-b]pyrazine derivatives and process for preparing same
JPS5926040U (en) 1982-08-12 1984-02-17 井出　正一 Rope tightening device
DE3432983A1 (en) 1983-09-07 1985-04-18 Lion Corp., Tokio/Tokyo 1,5-disubstituted 1H-pyrazolo[3,4-b]pyrazine derivatives and antitumour agents which contain them
JPH029895Y2 (en) 1984-11-08 1990-03-12
JPH0348656Y2 (en) 1985-05-10 1991-10-17
JPS62273979A (en) 1986-05-21 1987-11-28 Lion Corp 1,5-substituted-1h-pyrazolo(3,4-b)pyrazine derivative and antitumor agent containing said compound
JPS6310630A (en) 1986-06-23 1988-01-18 Teijin Ltd Production of aromatic polyamide-imide ether
JPS6317882A (en) 1986-07-09 1988-01-25 Lion Corp 5-substituted-1h-pyrazolo(3,4-b)pyrazine derivative and antitumor agent containing said compound
US4859672A (en) 1986-10-29 1989-08-22 Rorer Pharmaceutical Corporation Pyrido[2,3-d]pyrimidinone and imidazo[4,5-b]pyrimidinone
US4874803A (en) 1987-09-21 1989-10-17 Pennwalt Corporation Dianhydride coupled polymer stabilizers
DE3814549A1 (en) 1987-10-30 1989-05-18 Bayer Ag N-SUBSTITUTED DERIVATIVES OF 1-DESOXYNOJIRIMYCIN AND 1-DESOXYMANNONOJIRIMYCIN, METHOD FOR THE PRODUCTION AND USE THEREOF IN MEDICINAL PRODUCTS
JPH029895A (en) 1988-06-28 1990-01-12 Lion Corp Nucleoside analog compound and antitumor agent
DD280853A1 (en) 1989-03-21 1990-07-18 Akad Nauk Sssr BINDER FOR ELECTRODES, PREFERABLY FOR POLYMER ELECTRODES
US5159054A (en) 1989-05-16 1992-10-27 The United States Of America As Represented By The Secretary Of The Navy Synthesis of phthalonitrile resins containing ether and imide linkages
JP2845957B2 (en) 1989-07-17 1999-01-13 三井化学株式会社 Novel diphenols having imide ring and process for producing the same
US5726302A (en) 1989-09-15 1998-03-10 Gensia Inc. Water soluble adenosine kinase inhibitors
DE3937633A1 (en) 1989-11-11 1991-05-16 Bayer Ag HETEROCYCLIC COMPOUNDS AND THEIR USE AS PIGMENTS AND DYES
EP0506867B1 (en) 1989-12-28 1995-09-20 Hoechst Aktiengesellschaft Biscationic acid amide and acid imide derivatives as charge controllers
JPH0776201B2 (en) 1989-12-28 1995-08-16 ヘキスト・アクチェンゲゼルシャフト Acid amide- and -imide derivatives of biscation and method for producing the same
JP2883670B2 (en) 1990-03-23 1999-04-19 三井化学株式会社 Novel bisphenol having imide ring and method for producing the same
GB9113137D0 (en) 1990-07-13 1991-08-07 Ici Plc Thioxo heterocycles
WO1992006078A1 (en) 1990-10-03 1992-04-16 Commonwealth Scientific And Industrial Research Organisation Epoxy resins based on diaminobisimide compounds
JPH04158084A (en) 1990-10-22 1992-06-01 Fuji Photo Film Co Ltd Recording material
JPH04179576A (en) 1990-11-14 1992-06-26 Fuji Photo Film Co Ltd Recording material
JPH04328121A (en) 1991-04-26 1992-11-17 Sumitomo Bakelite Co Ltd Epoxy resin composition for sealing semiconductor
JP3147902B2 (en) 1991-06-14 2001-03-19 ファルマシア・アンド・アップジョン・カンパニー Imidazo [1,5-a] quinoxaline
DE4119767A1 (en) 1991-06-15 1992-12-17 Dresden Arzneimittel Prepn. of (pyrimid-2-yl-thio- or seleno-) acetic acid derivs. - by reacting the corresp. chloro:alkanoyl-amino cpd. with a rhodanide and water or an alcohol
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
JP3279635B2 (en) 1992-05-18 2002-04-30 鐘淵化学工業株式会社 Hydrosilyl group-containing imide compound
JP3232123B2 (en) 1992-05-20 2001-11-26 鐘淵化学工業株式会社 Curable composition
JPH07506836A (en) 1992-05-28 1995-07-27 コモンウェルス・サイエンティフィック・アンド・インダストリアル・リサーチ・オーガニゼイション Bismaleimide compound
EP0672044A4 (en) 1992-12-07 1997-08-20 Commw Scient Ind Res Org Bisnadimides.
WO1994015995A1 (en) 1993-01-11 1994-07-21 The Trustees Of The University Of Pennsylvania Polycyclic aromatic compounds having nonlinear optical properties
AU4293193A (en) 1993-04-28 1994-11-21 Du Pont Merck Pharmaceutical Company, The Novel trisubstituted aromatic amines useful for the treatment of cognitive deficits
US5536725A (en) 1993-08-25 1996-07-16 Fmc Corporation Insecticidal substituted-2,4-diamino-5,6,7,8-tetrahydroquinazolines
ES2193609T3 (en) 1993-11-30 2003-11-01 Searle & Co PIRAZOLIL-BENCENOSULFONAMIDAS SUBSTITUTED AND ITS USE AS INHIBITORS OF CYCLOOXYGENASE II.
BR9408531A (en) 1994-02-02 1997-08-05 Lilly Co Eli Hiv protease inhibitors and intermediates
US5480887A (en) 1994-02-02 1996-01-02 Eli Lilly And Company Protease inhibitors
DK0790997T3 (en) 1994-11-14 2000-08-21 Warner Lambert Co 6-Aryl-pyrido [2,3-d] pyrimidines and napthyridines to inhibit protein tyrosine kinase-induced cell proliferation
US7067664B1 (en) 1995-06-06 2006-06-27 Pfizer Inc. Corticotropin releasing factor antagonists
US5783577A (en) 1995-09-15 1998-07-21 Trega Biosciences, Inc. Synthesis of quinazolinone libraries and derivatives thereof
JPH09188812A (en) 1996-01-11 1997-07-22 Mitsui Toatsu Chem Inc Crystallization accelerator
AU2980797A (en) 1996-06-11 1998-01-07 Yoshitomi Pharmaceutical Industries, Ltd. Fused heterocyclic compounds and medicinal uses thereof
ATE232863T1 (en) 1996-08-06 2003-03-15 Pfizer 6,6- OR 6,7-BICYCLIC DERIVATIVES CONTAINING SUBSTITUTED PYRIDO OR PYRIMIDO GROUPS
US6184235B1 (en) 1996-08-14 2001-02-06 Warner-Lambert Company 2-phenyl benzimidazole derivatives as MCP-1 antagonists
JP3669783B2 (en) 1996-08-21 2005-07-13 三井化学株式会社 Organic electroluminescence device
US5994364A (en) 1996-09-13 1999-11-30 Schering Corporation Tricyclic antitumor farnesyl protein transferase inhibitors
WO1998018781A2 (en) 1996-10-28 1998-05-07 Versicor, Inc. Fused 2,4-pyrimidinedione combinatorial libraries, their preparation and the use of fused 2,4-pyrimidinediones derivatives as antimicrobial agents
US6057329A (en) 1996-12-23 2000-05-02 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives
ES2301194T3 (en) 1997-02-05 2008-06-16 Warner-Lambert Company Llc PIRIDO 2,3-D PYRIMIDINS AND 4-AMINOPIRIMIDINAS AS INHIBITORS OF THE CELL PROLIFERATION.
CA2285263C (en) 1997-04-11 2009-03-10 Abbott Laboratories Furopyridine, thienopyridine, pyrrolopyridine and related pyrimidine, pyridazine and triazine compounds useful in controlling chemical synaptic transmission
CA2291750A1 (en) 1997-05-28 1998-12-03 Rhone-Poulenc Rorer Pharmaceuticals Inc. Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
GB9716231D0 (en) 1997-07-31 1997-10-08 Amersham Int Ltd Base analogues
EP0994892A1 (en) 1997-08-11 2000-04-26 Cor Therapeutics, Inc. SELECTIVE FACTOR Xa INHIBITORS
EP1003745B1 (en) 1997-08-20 2004-12-29 Warner-Lambert Company Llc Naphthyridinones for inhibiting protein tyrosine kinase and cell cycle kinase mediated cellular proliferation
US6465484B1 (en) 1997-09-26 2002-10-15 Merck & Co., Inc. Angiogenesis inhibitors
JPH11171865A (en) 1997-12-04 1999-06-29 Yoshitomi Pharmaceut Ind Ltd Condensed heterocyclic compound
US6350749B1 (en) 1998-02-20 2002-02-26 Takeda Chemical Industries, Ltd. Aminoguanidine hydrazone derivatives, process for producing the same and drugs thereof
CA2332239A1 (en) 1998-05-15 1999-11-25 Guilford Pharmaceuticals Inc. Fused tricyclic compounds which inhibit parp activity
CN1138778C (en) * 1998-05-26 2004-02-18 沃尼尔·朗伯公司 Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidine sas inhibitors of cellular proliferation
US20040044012A1 (en) 1998-05-26 2004-03-04 Dobrusin Ellen Myra Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
AU4429799A (en) 1998-06-12 1999-12-30 Vertex Pharmaceuticals Incorporated Inhibitors of p38
JP4516690B2 (en) 1998-08-11 2010-08-04 ノバルティス アーゲー Isoquinoline derivatives having angiogenesis inhibitory activity
JP2000123973A (en) 1998-10-09 2000-04-28 Canon Inc Organic light emitting element
AU769989B2 (en) 1998-10-23 2004-02-12 F. Hoffmann-La Roche Ag Bicyclic nitrogen heterocycles
GB9823103D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
DE19912638A1 (en) 1999-03-20 2000-09-21 Bayer Ag Naphthylcarboxamide substituted sulfonamides
DE19920790A1 (en) 1999-05-06 2000-11-09 Bayer Ag Bis-sulfonamides with anti-HCMV activity
PE20010306A1 (en) 1999-07-02 2001-03-29 Agouron Pharma INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM USEFUL FOR THE INHIBITION OF PROTEIN KINASE
JP4041624B2 (en) 1999-07-21 2008-01-30 三井化学株式会社 Organic electroluminescence device
EA005423B1 (en) 1999-09-24 2005-02-24 Янссен Фармацевтика Н.В. Antiviral compositions
DE19946289A1 (en) 1999-09-28 2001-03-29 Basf Ag Benzodiazepine derivatives, their production and use
IL149100A0 (en) 1999-10-21 2002-11-10 Hoffmann La Roche Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase
DE60032623T2 (en) 1999-10-21 2007-10-11 F. Hoffmann-La Roche Ag ALKYLAMINO-SUBSTITUTED BICYCLIC HETEROCYCLES AS P38 PROTEIN KINASE INHIBITORS
TWI271406B (en) 1999-12-13 2007-01-21 Eisai Co Ltd Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same
JP2003519127A (en) 1999-12-29 2003-06-17 ワイス Tricyclic protein kinase inhibitors
MXPA02005989A (en) 2000-01-24 2002-10-23 Warner Lambert Co 3 aminoquinazolin 2,4 dione antibacterial agents.
CA2394525A1 (en) 2000-01-27 2001-08-02 Warner-Lambert Company Pyridopyrimidinone derivatives for treatment of neurodegenerative disease
ATE372337T1 (en) 2000-02-01 2007-09-15 Abbott Gmbh & Co Kg HETEROCYCLIC COMPOUNDS AND THEIR APPLICATION AS PARP INHIBITORS
ATE309999T1 (en) 2000-02-04 2005-12-15 Portola Pharm Inc PLATELE ADP RECEPTOR INHIBITORS
WO2001058899A1 (en) 2000-02-09 2001-08-16 Novartis Ag Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
DE60112268T2 (en) 2000-03-06 2006-05-24 Astrazeneca Ab USE OF QUINAZOLIN DERIVATIVES AS INHIBITORS OF ANGIOGENESIS
DE10012549A1 (en) 2000-03-15 2001-09-20 Bayer Ag New heterocyclic-substituted dihydropyrimidine derivatives useful for treatment of viral infections, especially hepatitis B infections
JP2001265031A (en) 2000-03-15 2001-09-28 Fuji Xerox Co Ltd Electrophotographic photoreceptor, process cartridge and electrophotographic device
CN101016296A (en) 2000-04-28 2007-08-15 阿卡蒂亚药品公司 Muscarinic agonists
AU2001264566A1 (en) 2000-05-05 2001-11-20 Cor Therapeutics, Inc. Heterobicyclic sulfonamides and their use as platelet adp receptor inhibitors
JP2004501918A (en) 2000-06-23 2004-01-22 ブリストル−マイヤーズ　スクイブ　ファーマ　カンパニー 1- (Heteroaryl-phenyl) -fused pyrazole derivatives as factor Xa inhibitors
PT1294358E (en) 2000-06-28 2004-12-31 Smithkline Beecham Plc MOORING PROCESS BY HUMIDITY
US20050009876A1 (en) 2000-07-31 2005-01-13 Bhagwat Shripad S. Indazole compounds, compositions thereof and methods of treatment therewith
EP1325006A2 (en) 2000-08-07 2003-07-09 Neurogen Corporation Heterocyclic compounds as ligands of the gaba a? receptor
RU2317988C2 (en) 2000-08-14 2008-02-27 Орто-Макнейл Фармасьютикал, Инк. Substituted pyrazoles, pharmaceutical composition based on thereof, using pharmaceutical composition and method for inhibition of cathepsin s activity
WO2002020011A2 (en) 2000-09-06 2002-03-14 Ortho Mcneil Pharmaceutical, Inc. A method for treating allergies using substituted pyrazoles
GB0025782D0 (en) 2000-10-20 2000-12-06 Pfizer Ltd Use of inhibitors
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
GB0100621D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VI
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
AP1699A (en) 2001-03-21 2006-12-26 Warner Lambert Co New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
US6998408B2 (en) 2001-03-23 2006-02-14 Bristol-Myers Squibb Pharma Company 6-5, 6-6, or 6-7 Heterobicycles as factor Xa inhibitors
JP2002296731A (en) 2001-03-30 2002-10-09 Fuji Photo Film Co Ltd Heat developable color image recording material
ATE449763T1 (en) 2001-04-16 2009-12-15 Eisai R&D Man Co Ltd 1H-INDAZOLE COMPOUNDS THAT INHIBIT JNK
ATE402164T1 (en) 2001-04-26 2008-08-15 Eisai R&D Man Co Ltd NITROGEN CONTAINING COMPOUND HAVING A CONDENSED RING AND PYRAZOLYL GROUP AS A SUBSTITUENT AND MEDICAL COMPOSITION THEREOF
US7279474B2 (en) 2001-04-30 2007-10-09 Glaxo Group Limited Substituted pyrrolo[2,3-d]pyrimidines as antagonists of the corticotropin releasing factor (CRF)
WO2002094825A1 (en) 2001-05-22 2002-11-28 Banyu Pharmaceutical Co., Ltd. Novel spiropiperidine derivative
US20030114448A1 (en) 2001-05-31 2003-06-19 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
EP1401830A2 (en) 2001-06-19 2004-03-31 Warner-Lambert Company LLC Quinazolinediones as antibacterial agents
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
WO2003000187A2 (en) 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel pyrazolo-and pyrrolo-pyrimidines and uses thereof
WO2003000690A1 (en) 2001-06-25 2003-01-03 Aventis Pharmaceuticals Inc. Synthesis of heterocyclic compounds employing microwave technology
US20040235867A1 (en) 2001-07-24 2004-11-25 Bilodeau Mark T. Tyrosine kinase inhibitors
HUP0401108A2 (en) 2001-08-07 2004-09-28 Banyu Pharmaceutical Co., Ltd. Spiro compounds, process for their preparation and pharmaceutical compositions containing them
EP1436291B1 (en) 2001-09-19 2009-01-14 Aventis Pharma S.A. Indolizines as kinase protein inhibitors
CN1582150B (en) 2001-10-30 2011-09-07 诺瓦提斯公司 Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity
CA2463822A1 (en) 2001-11-01 2003-05-08 Janssen Pharmaceutica N.V. Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors)
CA2465711A1 (en) 2001-11-07 2003-05-15 F. Hoffmann-La Roche Ag Aminopyrimidines and pyridines
JP4488740B2 (en) 2001-11-13 2010-06-23 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド Agents that modulate immune cell activation and methods of use thereof
GB0129476D0 (en) 2001-12-10 2002-01-30 Syngenta Participations Ag Organic compounds
GEP20063909B (en) 2002-01-22 2006-08-25 Warner Lambert Co 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d] PYRIMIDIN-7-ONES
CA2477657C (en) 2002-03-05 2011-04-26 Merck Frosst Canada & Co./Merck Frosst Canada & Cie Cathepsin cysteine protease inhibitors
US6815519B2 (en) 2002-03-22 2004-11-09 Chung-Shan Institute Of Science & Technology Acidic fluorine-containing poly (siloxane amideimide) silica hybrids
EP1492790A1 (en) 2002-04-03 2005-01-05 F. Hoffmann-La Roche Ag Imidazo fused compounds
MXPA04011320A (en) 2002-05-15 2005-08-16 Johnson & Johnson N-substituted tricyclic 3-aminopyrazoles as pdfg receptor inhibitors.
JP4499342B2 (en) 2002-05-16 2010-07-07 株式会社カネカ Method for producing nitrogen-containing organic compound containing SiH group
PT1551834E (en) 2002-05-23 2010-09-30 Novartis Vaccines & Diagnostic Substituted quinazolinone compounds
TW200406374A (en) 2002-05-29 2004-05-01 Novartis Ag Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
US7119111B2 (en) 2002-05-29 2006-10-10 Amgen, Inc. 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
PA8577501A1 (en) 2002-07-25 2004-02-07 Warner Lambert Co KINASE INHIBITORS
MXPA05001096A (en) 2002-07-29 2005-11-23 Rigel Pharmaceuticals Inc Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds.
ATE374201T1 (en) 2002-08-06 2007-10-15 Hoffmann La Roche 6-ALKOXYPYRIDOPYRIMIDINES AS INHIBITORS OF P-38 MAP KINASE
EP1388541A1 (en) 2002-08-09 2004-02-11 Centre National De La Recherche Scientifique (Cnrs) Pyrrolopyrazines as kinase inhibitors
US7084270B2 (en) 2002-08-14 2006-08-01 Hoffman-La Roche Inc. Pyrimido compounds having antiproliferative activity
GB0220187D0 (en) 2002-08-30 2002-10-09 Novartis Ag Organic compounds
GB0223349D0 (en) 2002-10-08 2002-11-13 Merck Sharp & Dohme Therapeutic agents
US7129351B2 (en) 2002-11-04 2006-10-31 Hoffmann-La Roche Inc. Pyrimido compounds having antiproliferative activity
TW200413381A (en) 2002-11-04 2004-08-01 Hoffmann La Roche Novel amino-substituted dihydropyrimido [4,5-d]pyrimidinone derivatives, their manufacture and use as pharmaceutical agents
WO2004043367A2 (en) 2002-11-06 2004-05-27 Bristol-Myers Squibb Company Fused heterocyclic compounds and use thereof
CL2003002353A1 (en) 2002-11-15 2005-02-04 Vertex Pharma COMPOUNDS DERIVED FROM DIAMINOTRIAZOLS, INHIBITORS D ELA PROTEINA QUINASA; PHARMACEUTICAL COMPOSITION; PREPARATION PROCEDURE; AND ITS USE OF THE COMPOUND IN THE TREATMENT OF DISEASES OF ALLERGIC DISORDERS, PROLIFERATION, AUTOIMMUNES, CONDIC
KR20050075028A (en) * 2002-11-18 2005-07-19 에프. 호프만-라 로슈 아게 Diazinopyrimidines
MXPA05005547A (en) 2002-11-28 2005-07-26 Schering Ag Chk-, pdk- and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents.
EP1567497B1 (en) 2002-12-06 2009-09-23 Purdue Research Foundation Pyridines for treating injured mammalian nerve tissue
US7759336B2 (en) 2002-12-10 2010-07-20 Ono Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic compounds and medicinal use thereof
UA80171C2 (en) 2002-12-19 2007-08-27 Pfizer Prod Inc Pyrrolopyrimidine derivatives
US7098332B2 (en) 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
AU2003288675B2 (en) 2002-12-23 2010-07-22 Medimmune Limited Antibodies against PD-1 and uses therefor
JP2004203749A (en) 2002-12-24 2004-07-22 Kanegafuchi Chem Ind Co Ltd METHOD FOR PRODUCING NITROGEN-CONTAINING ORGANIC COMPOUND CONTAINING SiH GROUP
BRPI0406809A (en) 2003-01-17 2005-12-27 Warner Lambert Co 2-Aminopyridine substituted heterocycles as cell proliferation inhibitors
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
US7135469B2 (en) 2003-03-18 2006-11-14 Bristol Myers Squibb, Co. Linear chain substituted monocyclic and bicyclic derivatives as factor Xa inhibitors
JP4887139B2 (en) 2003-03-25 2012-02-29 武田薬品工業株式会社 Dipeptidyl peptidase inhibitor
GB0308208D0 (en) 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
KR100864393B1 (en) * 2003-04-10 2008-10-20 에프. 호프만-라 로슈 아게 Pyrimido compounds
RU2328497C2 (en) 2003-05-05 2008-07-10 Ф.Хоффманн-Ля Рош Аг Condensed pirimidine derivative and pharmaceutics with crf related activity
JP2004346145A (en) 2003-05-21 2004-12-09 Teijin Ltd Imide composition, resin composition comprising the same and its manufacturing method
WO2004112793A1 (en) 2003-05-23 2004-12-29 Chiron Corporation Guanidino-substituted quinazolinone compounds as mc4-r agonists
KR101099409B1 (en) 2003-06-06 2011-12-27 아렉시스 악티에볼라그 Use of fused heterocyclic compounds as scce inhibitors for the treatment of skin conditions or cancer
IL156495A0 (en) 2003-06-17 2004-01-04 Prochon Biotech Ltd Use of fgfr3 antagonists for treating t cell mediated diseases
EP1637523A4 (en) 2003-06-18 2009-01-07 Ube Industries Process for producing pyrimidin-4-one compound
JP2005015395A (en) 2003-06-26 2005-01-20 Japan Science & Technology Agency New pyrimidopyrimidine nucleoside and its structural analog
US7618975B2 (en) 2003-07-03 2009-11-17 Myriad Pharmaceuticals, Inc. 4-arylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof
AR045037A1 (en) 2003-07-10 2005-10-12 Aventis Pharma Sa TETRAHIDRO-1H-PIRAZOLO [3,4-C] SUBSTITUTED PYRIDINS, COMPOSITIONS THAT CONTAIN THEM AND ITS USE.
BRPI0413005A (en) 2003-07-29 2006-09-26 Irm Llc compounds and compositions as protein kinase inhibitors
US7390820B2 (en) 2003-08-25 2008-06-24 Amgen Inc. Substituted quinolinone derivatives and methods of use
EP1675858A2 (en) 2003-09-03 2006-07-05 Neurogen Corporation 5-aryl-pyrazolo [4,3-d] pyrimidines, pyridines, and pyrazines and related compounds
NZ546611A (en) 2003-09-18 2010-02-26 Conforma Therapeutics Corp Novel heterocyclic compounds as HSP90-inhibitors
WO2005028478A1 (en) 2003-09-19 2005-03-31 Gilead Sciences, Inc. Aza-quinolinol phosphonate integrase inhibitor compounds
AR045944A1 (en) 2003-09-24 2005-11-16 Novartis Ag ISOQUINOLINE DERIVATIVES 1.4-DISPOSED
WO2005040119A1 (en) 2003-10-01 2005-05-06 Bayer Healthcare Ag Tetrahydro-naphthalene and urea derivatives
AU2004279427B2 (en) 2003-10-08 2008-07-03 Irm Llc Compounds and compositions as protein kinase inhibitors
CN1897950A (en) 2003-10-14 2007-01-17 惠氏公司 Fused-aryl and heteroaryl derivatives and methods of their use
US20090099165A1 (en) 2003-10-14 2009-04-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
JP2007511596A (en) 2003-11-17 2007-05-10 ファイザー・プロダクツ・インク Pyrrolopyrimidine compounds useful in the treatment of cancer
WO2005056524A2 (en) 2003-12-09 2005-06-23 Euro-Celtique S.A. Therapeutic agents useful for treating pain
WO2005066162A1 (en) 2003-12-23 2005-07-21 Human Biomolecular Research Institute Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer
KR100703068B1 (en) 2003-12-30 2007-04-05 에스케이케미칼주식회사 Novel pyridine derivatives, process for preparing thereof and pharmaceutical compositions containing them
US20050222171A1 (en) 2004-01-22 2005-10-06 Guido Bold Organic compounds
AU2005206562A1 (en) 2004-01-23 2005-08-04 Amgen Inc. Vanilloid receptor ligands and their use in treatments
CN1909907B (en) 2004-01-23 2010-06-23 詹森药业有限公司 Quinoline derivatives and use thereof for preparing mycobacterial inhibitors
AU2005208938A1 (en) 2004-01-29 2005-08-11 Elixir Pharmaceuticals, Inc Anti-viral therapeutics
GB0402137D0 (en) 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
PL1713806T3 (en) 2004-02-14 2013-09-30 Irm Llc Compounds and compositions as protein kinase inhibitors
JP2007523151A (en) 2004-02-18 2007-08-16 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 2- (Pyridin-3-ylamino) -pyrido [2,3-d] pyrimidin-7-one
RU2006134021A (en) 2004-02-27 2008-04-10 Ф.Хоффманн-Ля Рош Аг (Ch) Heteroaryl-Condensed Pyrazole Derivatives
AU2005219525B2 (en) 2004-02-27 2011-08-18 F. Hoffmann-La Roche Ag Fused derivatives of pyrazole
WO2005087765A1 (en) 2004-03-04 2005-09-22 Arena Pharmaceuticals, Inc. Ligands of follicle stimulating hormone receptor and methods of use thereof
WO2005085210A1 (en) 2004-03-10 2005-09-15 Ono Pharmaceutical Co., Ltd. Nitriles and medicinal compositions containing the same as the active ingredient
KR100861434B1 (en) 2004-03-29 2008-10-02 미쓰이 가가쿠 가부시키가이샤 Novel compound and organic electronic device using such compound
WO2005105097A2 (en) 2004-04-28 2005-11-10 Gpc Biotech Ag Pyridopyrimidines for treating inflammatory and other diseases
JP2005320288A (en) 2004-05-10 2005-11-17 Mitsui Chemicals Inc Tetracarboxylic acid derivative, electrophotographic photoreceptor given by using the compound, and electrophotographic device
US20050256309A1 (en) 2004-05-12 2005-11-17 Altenbach Robert J Tri-and bi-cyclic heteroaryl histamine-3 receptor ligands
CA2566160C (en) 2004-05-27 2011-01-18 Pfizer Products Inc. Pyrrolopyrimidine derivatives useful in cancer treatment
PE20060426A1 (en) 2004-06-02 2006-06-28 Schering Corp TARTARIC ACID DERIVATIVES AS INHIBITORS OF MMPs, ADAMs, TACE AND TNF-alpha
EP1758892B1 (en) 2004-06-10 2012-10-17 Irm Llc Compounds and compositions as protein kinase inhibitors
RU2364596C2 (en) 2004-06-11 2009-08-20 Джапан Тобакко Инк. DERIVATIVES OF 5-AMINO-2,4,7-TRIOXO-3,4,7,8-TETRAHYDRO-2H-PYRIDO[2,3-d]PYRIMIDINE, POSSESSING ANTI-TUMOR ACTIVITY
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
JP2006028027A (en) 2004-07-12 2006-02-02 Mitsui Chemicals Inc Tetracarboxylic acid derivative, electrophotographic photoconductor using the compound and electrohptographic apparatus
EP1789399A1 (en) 2004-08-31 2007-05-30 AstraZeneca AB Quinazolinone derivatives and their use as b-raf inhibitors
JP2008509964A (en) 2004-08-31 2008-04-03 エフ．ホフマン−ラ ロシュ アーゲー Amide derivatives of 7-amino-3-phenyl-dihydropyrimido [4,5-D] pyrimidinone, their preparation and use as protein kinase inhibitors
US7655651B2 (en) 2004-08-31 2010-02-02 Hoffmann-La Roche Inc. Amide derivatives of 3-phenyl-dihydropyrimido[4,5-d]pyrimidinones, their manufacture and use as pharmaceutical agents
DE102004042667A1 (en) 2004-09-01 2006-03-30 Ewald Dörken Ag Multilayered building wall
KR101165653B1 (en) 2004-09-10 2012-07-17 우베 고산 가부시키가이샤 Modified polyimide resin and curable resin composition
EP1811844A4 (en) 2004-09-14 2009-12-02 Minerva Biotechnologies Corp Methods for diagnosis and treatment of cancer
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
WO2006038112A1 (en) 2004-10-01 2006-04-13 Warner-Lambert Company Llc Use of kinase inhibitors to promote neochondrogenesis
FR2876582B1 (en) 2004-10-15 2007-01-05 Centre Nat Rech Scient Cnrse USE OF PYRROLO-PYRAZINE DERIVATIVES FOR THE MANUFACTURE OF MEDICAMENTS FOR THE TREATMENT OF MUCOVISCIDOSIS AND DISEASES ASSOCIATED WITH A DEFECT OF ADDRESSING PROTEINS IN CELLS
US20060135553A1 (en) 2004-10-28 2006-06-22 Campbell David A Imidazole derivatives
US7855205B2 (en) 2004-10-29 2010-12-21 Janssen Pharmaceutica Nv Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
CA2587276A1 (en) 2004-11-08 2006-05-18 Baxter International Inc. Nanoparticulate compositions of tubulin inhibitor compounds
JP2008520700A (en) 2004-11-18 2008-06-19 インサイト・コーポレイション Inhibitors of 11-β hydroxyl steroid dehydrogenase type I and methods of use thereof
US20060122185A1 (en) 2004-11-22 2006-06-08 Jeremy Green Bicyclic inhibitors of Rho kinase
AU2005309019A1 (en) 2004-11-24 2006-06-01 Novartis Ag Combinations of JAK inhibitors and at least one of Bcr-Abl, Flt-3, FAK or RAF kinase inhibitors
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
AU2005316668B2 (en) 2004-12-13 2012-09-06 Millennium Pharmaceuticals, Inc. Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as RAF kinase inhibitors
WO2006074293A2 (en) 2005-01-07 2006-07-13 President And Fellows Of Harvard College Bicyclic dihydropyrimidines as eg5 inhibitors
DE102005008310A1 (en) 2005-02-17 2006-08-24 Schering Ag Use of CDKII inhibitors for fertility control
AU2006219643A1 (en) 2005-03-01 2006-09-08 Pfizer Limited Use of PDE7 inhibitors for the treatment of neuropathic pain
US7297700B2 (en) 2005-03-24 2007-11-20 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
WO2006105448A2 (en) 2005-03-30 2006-10-05 Minerva Biotechnologies Corporation Proliferation of muc1 expressing cells
JP2006284843A (en) 2005-03-31 2006-10-19 Mitsui Chemicals Inc Electrophotographic photoreceptor using tetracarboxylic acid derivative and electrophotographing device
US20060223993A1 (en) 2005-04-01 2006-10-05 Connor Daniel M Colorant compounds, intermediates, and compositions
JP2006316054A (en) 2005-04-15 2006-11-24 Tanabe Seiyaku Co Ltd High-conductance type calcium-sensitive k channel opening agent
KR100781704B1 (en) 2005-04-20 2007-12-03 에스케이케미칼주식회사 Novel pyridine derivatives, process for preparing thereof and pharmaceutical compositions containing them
MX2007013595A (en) 2005-05-04 2008-01-24 Renovis Inc Fused heterocyclic compounds, and compositions and uses thereof.
CN109485727A (en) 2005-05-09 2019-03-19 小野药品工业株式会社 The human monoclonal antibodies of programmed death-1 (PD-1) and the method for carrying out treating cancer using anti-PD-1 antibody
WO2006124731A2 (en) 2005-05-12 2006-11-23 Irm Llc Compounds and compositions as protein kinase inhibitors
ATE492545T1 (en) 2005-05-13 2011-01-15 Irm Llc COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
WO2006135821A2 (en) 2005-06-09 2006-12-21 Achille Carlisle Tisdelle Vehicular head and neck safety system and method
GB0512844D0 (en) 2005-06-23 2005-08-03 Novartis Ag Organic compounds
MX2007015942A (en) 2005-07-01 2008-03-07 Medarex Inc Human monoclonal antibodies to programmed death ligand 1 (pd-l1).
EP1915377A1 (en) 2005-07-22 2008-04-30 Sunesis Pharmaceuticals, Inc. Pyrazolo pyrimidines useful as aurora kinase inhibitors
ES2270715B1 (en) 2005-07-29 2008-04-01 Laboratorios Almirall S.A. NEW DERIVATIVES OF PIRAZINA.
EP1910369A1 (en) 2005-07-29 2008-04-16 Astellas Pharma Inc. Fused heterocycles as lck inhibitors
JP2009504665A (en) 2005-08-09 2009-02-05 アイアールエム・リミテッド・ライアビリティ・カンパニー Compounds and compositions as protein kinase inhibitors
EP1919924A2 (en) 2005-08-16 2008-05-14 Irm, Llc Compounds and compositions as protein kinase inhibitors
KR101011958B1 (en) 2005-08-25 2011-01-31 에프. 호프만-라 로슈 아게 Fused pyrazole as ?38 map kinase inhibitors
US7678917B2 (en) 2005-09-01 2010-03-16 Hoffman-La Roche Inc. Factor Xa inhibitors
DE602006011482D1 (en) 2005-09-06 2010-02-11 Smithkline Beecham Corp REGIOSELECTIVE PROCESS FOR THE PREPARATION OF BENZIMIDAZOL THIOPHENES
AU2006289838B2 (en) 2005-09-15 2011-08-18 Aska Pharmaceutical Co., Ltd. Heterocyclic compound, and production process and use thereof
US20070116984A1 (en) 2005-09-21 2007-05-24 Doosan Corporation Spiro-compound for electroluminescent display device and electroluminescent display device comprising the same
MX2008004024A (en) 2005-09-23 2009-02-27 Schering Corp Fused tetracyclic mglur1 antagonists as therapeutic agents.
DE102005048072A1 (en) 2005-09-24 2007-04-05 Bayer Cropscience Ag Thiazoles as fungicides
AU2006302148B2 (en) 2005-10-07 2012-12-06 Exelixis, Inc. Pyridopyrimidinone inhibitors of PI3Kalpha
CN103819416A (en) 2005-10-07 2014-05-28 埃克塞里艾克西斯公司 N-(3-amino-quinoxalin-2-yl)-sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
WO2007061554A2 (en) 2005-10-21 2007-05-31 Purdue Research Foundation Dosage of 4-aminopyridine derivatives for treatment of central nervous system injuries
BRPI0617891A2 (en) 2005-10-26 2011-08-09 Boehringer Ingelheim Int (hetero) aryl compounds having mch antagonist activity, physiologically acceptable salts thereof, composition, pharmaceutical composition as well as use and preparation of said compounds
WO2007053498A1 (en) 2005-11-01 2007-05-10 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of ccr2
WO2007053452A1 (en) 2005-11-01 2007-05-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US8604042B2 (en) 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
JP5116687B2 (en) 2005-11-02 2013-01-09 バイエル・ファルマ・アクチェンゲゼルシャフト Pyrrolo [2,1-f] [1,2,4] triazin-4-ylamine IGF-1R kinase inhibitors for the treatment of cancer and other hyperproliferative diseases
US20070161645A1 (en) 2005-11-02 2007-07-12 Targegen, Inc. Thiazole inhibitors targeting resistant kinase mutations
NZ568292A (en) 2005-11-10 2011-08-26 Msd Kk Spiro[cyclohexane-1,1'-(3'H)-4'-azaisobenzofuran]-4-carboxamide derivatives
DK1954274T3 (en) 2005-11-10 2011-01-31 Chemocentryx Inc Substituted quinolones and methods of use
WO2007058626A1 (en) 2005-11-16 2007-05-24 S*Bio Pte Ltd Indazole compounds
WO2007058392A1 (en) 2005-11-21 2007-05-24 Japan Tobacco Inc. Heterocyclic compound and medicinal application thereof
KR20130141706A (en) 2005-12-02 2013-12-26 바이엘 헬스케어 엘엘씨 Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
PE20070855A1 (en) 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp DERIVATIVES OF 4-AMINO-PYRROLOTRIAZINE SUBSTITUTE AS KINASE INHIBITORS
CA2632512A1 (en) 2005-12-08 2007-06-14 Millennium Pharmaceuticals, Inc. Bicyclic compounds with kinase inhibitory activity
WO2007066189A2 (en) 2005-12-09 2007-06-14 Pfizer Products Inc. Salts, prodrugs and formulations of 1-[5-(4-amino-7-isopropyl-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2-methoxy-phenyl]-3-(2,4-dichloro-phenyl)-urea
WO2007120339A1 (en) 2005-12-19 2007-10-25 Genentech, Inc. Pyrimidine kinase inhibitors
BRPI0620408B8 (en) 2005-12-21 2021-05-25 Novartis Ag pyrimidinyl aryl urea derivatives being FGF inhibitors, their uses, and pharmaceutical preparation
US7998959B2 (en) 2006-01-12 2011-08-16 Incyte Corporation Modulators of 11-β hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
UY30118A1 (en) 2006-01-31 2007-06-29 Tanabe Seiyaku Co AMIS TRISUSTITUDE COMPUTER
US7427625B2 (en) 2006-02-08 2008-09-23 Janssen Pharmaceutica, N.V. Substituted thiatriazaacenaphthylene-6-carbonitrile kinase inhibitors
WO2007093901A1 (en) 2006-02-17 2007-08-23 Pfizer Limited 3 -deazapurine derivatives as tlr7 modulators
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US8349850B2 (en) 2006-03-28 2013-01-08 Atir Holding S.A. Heterocyclic compounds and uses thereof in the treatment of sexual disorders
CN101460161A (en) 2006-03-29 2009-06-17 弗尔德里克斯制药股份有限公司 Inhibition of alpha-synuclein toxicity
JP2010505739A (en) 2006-04-06 2010-02-25 ウイスコンシン アラムニ リサーチ ファンデーション 2-Methylene-1α, 25-dihydroxy-19,21-dinorvitamin D3 analog and use thereof
JP2009533426A (en) 2006-04-13 2009-09-17 アストラゼネカ・アクチエボラーグ Thioxanthine derivatives and their use as MPO inhibitors
GB0608386D0 (en) 2006-04-27 2006-06-07 Senexis Ltd Compounds
EP2024342A2 (en) 2006-05-01 2009-02-18 Pfizer Products Incorporated Substituted 2-amino-fused heterocyclic compounds
ATE499374T1 (en) 2006-05-11 2011-03-15 Irm Llc COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
WO2007136465A2 (en) * 2006-05-15 2007-11-29 Irm Llc Compositions and methods for fgf receptor kinases inhibitors
WO2007143600A2 (en) 2006-06-05 2007-12-13 Incyte Corporation Sheddase inhibitors combined with cd30-binding immunotherapeutics for the treatment of cd30 positive diseases
DE102006027156A1 (en) 2006-06-08 2007-12-13 Bayer Schering Pharma Ag New sulfimide compounds are protein kinase inhibitors useful to treat e.g. cancer, Hodgkin's lymphoma, Kaposi's sarcoma, cardiovascular disease, Crohn's disease, endometriosis and hemangioma
TW200808179A (en) 2006-06-16 2008-02-16 Albemarle Corp Methods of reducing or eliminating salmonella in reptiles and/or their eggs
CA2656825C (en) 2006-06-22 2013-12-10 Prana Biotechnology Limited Method of treatment and agents useful for same
MX2008016523A (en) 2006-06-30 2009-01-19 Astrazeneca Ab Pyrimidine derivatives useful in the treatment of cancer.
US20090281115A1 (en) 2006-06-30 2009-11-12 Board of Regents, The University of Texas System, a Texas University Inhibitors of c-kit and uses thereof
US8258129B2 (en) 2006-07-06 2012-09-04 Boehringer Ingelheim International Gmbh 4-heterocycloalkylpyri(mi)dines, process for the preparation thereof and their use as medicaments
US8030487B2 (en) 2006-07-07 2011-10-04 Targegen, Inc. 2-amino—5-substituted pyrimidine inhibitors
TW200811134A (en) 2006-07-12 2008-03-01 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2008012635A2 (en) 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents
WO2008021851A2 (en) 2006-08-09 2008-02-21 Smithkline Beecham Corporation Novel compounds as antagonists or inverse agonists for opioid receptors
JP2010500994A (en) 2006-08-16 2010-01-14 エグゼリクシス， インコーポレイテッド Methods of using PI3K and MEK modulators
DE102006041382A1 (en) 2006-08-29 2008-03-20 Bayer Schering Pharma Ag Carbamoyl sulfoximides as protein kinase inhibitors
CA2974246C (en) 2006-09-01 2020-02-25 Senhwa Biosciences, Inc. Tricyclic heteroaryl compounds and their use as protein modulators
AU2007338601C1 (en) 2006-09-05 2014-07-24 Emory University Tyrosine kinase inhibitors for prevention or treatment of infection
US20100160292A1 (en) 2006-09-11 2010-06-24 Cgi Pharmaceuticals, Inc Kinase Inhibitors, and Methods of Using and Identifying Kinase Inhibitors
US7897762B2 (en) 2006-09-14 2011-03-01 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of proliferative diseases
CA2664095A1 (en) 2006-09-21 2008-03-27 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted difluorobenzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
PE20080925A1 (en) 2006-09-22 2008-09-04 Glaxo Group Ltd PYRROLO [2,3-b] PYRIDINE DERIVATIVES AS KINASE INHIBITORS, IN PARTICULAR IKK2 INHIBITORS (OR IKK BETA)
CA2664375A1 (en) 2006-09-28 2008-04-03 Novartis Ag Pyrazolo [1, 5-a] pyrimidine derivatives and their therapeutic use
BRPI0719797A8 (en) 2006-10-02 2017-12-26 Novartis Ag COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
WO2008052934A1 (en) 2006-10-30 2008-05-08 Glaxo Group Limited Novel substituted pyrimidines as cysteine protease inhibitors
US7858645B2 (en) 2006-11-01 2010-12-28 Hoffmann-La Roche Inc. Indazole derivatives
JP5244118B2 (en) 2006-11-10 2013-07-24 ブリストル−マイヤーズ スクイブ カンパニー Novel kinase inhibitor
US7902363B2 (en) 2006-11-17 2011-03-08 Polyera Corporation Diimide-based semiconductor materials and methods of preparing and using the same
WO2008063583A1 (en) 2006-11-17 2008-05-29 Polyera Corporation Acene-based organic semiconductor materials and methods of preparing and using the same
KR20080045536A (en) 2006-11-20 2008-05-23 에스케이케미칼주식회사 A pharmaceutical compositions containing pyridine derivatives as an effective ingredient for the prevention and treatment of hepatitis or the liver protection
JP2010513278A (en) 2006-12-13 2010-04-30 シェーリング コーポレイション Method for treating cancer using IGF1R inhibitor
WO2008071455A1 (en) 2006-12-15 2008-06-19 Bayer Schering Pharma Aktiengesellschaft Bicyclic acyltryptophanols
WO2008074068A1 (en) 2006-12-20 2008-06-26 Prana Biotechnology Limited Substituted quinoline derivatives as antiamyloidogeneic agents
US7737149B2 (en) 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
CA2672172C (en) 2006-12-22 2016-05-03 Astex Therapeutics Limited Bicyclic heterocyclic compounds as fgfr inhibitors
AU2007336933A1 (en) 2006-12-22 2008-07-03 Novartis Ag Heteroaryl-heteroaryl compounds as CDK inhibitors for the treatment of cancer, inflammation and viral infections
CN101679409B (en) 2006-12-22 2014-11-26 Astex治疗学有限公司 Bicyclic heterocyclic derivative compound, pharmaceutical compositions and uses thereof
FR2911140B1 (en) 2007-01-05 2009-02-20 Sanofi Aventis Sa NOVEL 2-ANILINO 4-HETEROARYL PYRIMIDES DERIVATIVES, THEIR PREPARATION AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS, AND IN PARTICULAR AS INHIBITORS OF IKK
US7893265B2 (en) 2007-01-08 2011-02-22 Polyera Corporation Methods for preparing arene-BIS (dicarboximide)-based semiconducting materials and related intermediates for preparing same
CN101007778A (en) 2007-01-10 2007-08-01 复旦大学 Chain-prolonged type fluorenyl bimaleimide and its preparation method
CA2675288A1 (en) 2007-01-12 2008-07-17 Astellas Pharma Inc. Condensed pyridine compound
JP2010515760A (en) 2007-01-12 2010-05-13 バイオクライスト ファーマシューティカルズ， インコーポレイテッド Antiviral nucleoside analogues
FR2911604B1 (en) 2007-01-19 2009-04-17 Sanofi Aventis Sa N- (HETEROARYL-1H-INDOLE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
JP5358962B2 (en) 2007-02-06 2013-12-04 住友化学株式会社 Composition and light-emitting device using the composition
JP2008198769A (en) 2007-02-13 2008-08-28 Nippon Steel Chem Co Ltd Organic electroluminescence (el) element
BRPI0808422A2 (en) 2007-03-06 2015-06-23 Novartis Ag Bicyclic Organic Compounds Suitable for the Treatment of Inflammatory or Allergic Conditions
JP2010520292A (en) 2007-03-07 2010-06-10 アラントス・フアーマシユーテイカルズ・ホールデイング・インコーポレイテツド Metalloprotease inhibitors containing heterocyclic moieties
ES2557930T3 (en) 2007-03-12 2016-01-29 Ym Biosciences Australia Pty Ltd Phenylaminopyrimidine compounds and uses thereof
US20080234262A1 (en) 2007-03-21 2008-09-25 Wyeth Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors
EP2364976B1 (en) 2007-03-21 2014-10-08 EPIX Pharmaceuticals, Inc. S1P receptor modulating compounds and use thereof
CA2680783C (en) 2007-03-23 2012-04-24 Amgen Inc. Heterocyclic compounds and their uses
EP2896624B1 (en) 2007-03-28 2016-07-13 Atir Holding S.A. Heterotricyclic compounds as serotonergic and/or dopaminergic agents and uses thereof
KR20080091948A (en) 2007-04-10 2008-10-15 에스케이케미칼주식회사 A pharmaceutical compositions containing lactam type pyridine derivatives as an effective ingredient for the prevention and treatment of ischemia
US20100112211A1 (en) 2007-04-12 2010-05-06 Advanced Technology Materials, Inc. Zirconium, hafnium, titanium, and silicon precursors for ald/cvd
JP2010524941A (en) 2007-04-20 2010-07-22 シェーリング コーポレイション Pyrimidinone derivatives and methods for their use
EP1985612A1 (en) 2007-04-26 2008-10-29 Bayer Schering Pharma Aktiengesellschaft Arymethylen substituted N-Acyl-gamma-aminoalcohols
EP1990342A1 (en) * 2007-05-10 2008-11-12 AEterna Zentaris GmbH Pyridopyrazine Derivatives, Process of Manufacturing and Uses thereof
JP2010526823A (en) 2007-05-10 2010-08-05 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Quinoxaline derivatives as PI3 kinase inhibitors
WO2008144253A1 (en) 2007-05-14 2008-11-27 Irm Llc Protein kinase inhibitors and methods for using thereof
GB2449293A (en) 2007-05-17 2008-11-19 Evotec Compounds having Hsp90 inhibitory activity
SG185285A1 (en) 2007-06-03 2012-11-29 Univ Vanderbilt Benzamide mglur5 positive allosteric modulators and methods of making and using same
JP2010529120A (en) 2007-06-07 2010-08-26 メルク・シャープ・エンド・ドーム・コーポレイション Tricyclic anilide heterocyclic CGRP receptor antagonist
US7928111B2 (en) 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
US8633186B2 (en) 2007-06-08 2014-01-21 Senomyx Inc. Modulation of chemosensory receptors and ligands associated therewith
SI2168966T1 (en) 2007-06-15 2017-03-31 Msd K.K. Bicycloaniline derivative
DK2170959T3 (en) 2007-06-18 2014-01-13 Merck Sharp & Dohme ANTIBODIES AGAINST HUMAN PROGRAMMED DEATH RECEPTOR PD-1
EP2018859A1 (en) 2007-07-26 2009-01-28 Bayer Schering Pharma Aktiengesellschaft Arylmethylene substituted N-acyl-beta-amino alcohols
ATE522249T1 (en) 2007-07-26 2011-09-15 Novartis Ag ORGANIC COMPOUNDS
EP2020404A1 (en) 2007-08-01 2009-02-04 Bayer Schering Pharma Aktiengesellschaft Cyanomethyl substituted N-Acyl Tryptamines
WO2009021083A1 (en) 2007-08-09 2009-02-12 Smithkline Beecham Corporation Quinoxaline derivatives as pi3 kinase inhibitors
WO2009019518A1 (en) 2007-08-09 2009-02-12 Astrazeneca Ab Pyrimidine compounds having a fgfr inhibitory effect
WO2009029625A1 (en) 2007-08-27 2009-03-05 Kalypsys, Inc. 4- [heterocyclyl-methyl] -8-fluoro-quinolin-2-ones useful as nitric oxide synthase inhibitors
US7960400B2 (en) 2007-08-27 2011-06-14 Duquesne University Of The Holy Ghost Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof
US8530480B2 (en) 2007-09-04 2013-09-10 The Scripps Research Institute Substituted pyrimidinyl-amines as protein kinase inhibitors
WO2009030871A1 (en) 2007-09-07 2009-03-12 Vernalis R & D Ltd Pyrrolopyrimidine derivatives having hsp90 inhibitory activity
TW200920357A (en) 2007-09-10 2009-05-16 Curis Inc HSP90 inhibitors containing a zinc binding moiety
JP5792955B2 (en) 2007-10-01 2015-10-14 アイシス ファーマシューティカルズ， インコーポレーテッド Antisense modulation of fibroblast growth factor receptor 4 expression
CA2701406C (en) 2007-10-05 2016-01-26 Banyu Pharmaceutical Co., Ltd. Benzoxazinone derivative
EP2209775A1 (en) 2007-10-09 2010-07-28 UCB Pharma, S.A. Heterobicyclic compounds as histamine h4-receptor antagonists
WO2009049018A1 (en) 2007-10-10 2009-04-16 Syndax Pharmaceuticals, Inc. Novel compounds and methods of using them
WO2009046606A1 (en) 2007-10-11 2009-04-16 Shanghai Institute Of Materia Medica, Cas Pyrimidinyl-propionic acid derivatives and their use as ppar agonists
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
JP5273052B2 (en) 2007-10-13 2013-08-28 コニカミノルタ株式会社 Organic electroluminescence element, display device and lighting device
US8129371B2 (en) 2007-10-16 2012-03-06 Wyeth Llc Thienopyrimidine and pyrazolopyrimidine compounds and their use as mTOR kinase and PI3 kinase inhibitors
US8367662B2 (en) 2007-10-17 2013-02-05 Novartis Ag Organic compounds
RU2007139634A (en) 2007-10-25 2009-04-27 Сергей Олегович Бачурин (RU) NEW THIAZOLE-, TRIAZOLE- OR OXADIAZOLE-CONTAINING TETRACYCLIC COMPOUNDS
JP2011500778A (en) 2007-10-25 2011-01-06 アストラゼネカ・アクチエボラーグ Pyridine and pyrazine derivatives-083
WO2009056886A1 (en) 2007-11-01 2009-05-07 Astrazeneca Ab Pyrimidine derivatives and their use as modulators of fgfr activity
CN104311563B (en) 2007-11-28 2016-12-07 达那-法伯癌症研究所 The small molecule myristate inhibitors of BCR-ABL and using method thereof
EP2231620A1 (en) 2007-12-03 2010-09-29 Boehringer Ingelheim International GmbH Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation
CN101945867A (en) 2007-12-19 2011-01-12 安姆根有限公司 Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
WO2009086303A2 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
JP2011507902A (en) 2007-12-21 2011-03-10 ワイス・エルエルシー Imidazo [1,2-b] pyridazine compounds as modulators of liver X receptors
WO2009086509A2 (en) 2007-12-27 2009-07-09 Purdue Research Foundation Reagents for biomolecular labeling, detection and quantification employing raman spectroscopy
FR2926297B1 (en) 2008-01-10 2013-03-08 Centre Nat Rech Scient INHIBITORY CHEMICAL MOLECULES IN THE SPLICE MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICE ANOMALIES.
WO2009092764A1 (en) 2008-01-24 2009-07-30 Ucb Pharma, S.A. Compounds comprising a cyclobutoxy group
KR20100119777A (en) 2008-01-24 2010-11-10 알라 캠, 엘엘씨 Substituted cycloalcano[e and d] pyrazolo [1,5-a]pyrimidines/antagonists of serotonin 5-ht6 receptors and methods for production and the use thereof
EA017805B1 (en) 2008-01-24 2013-03-29 Андрей Александрович ИВАЩЕНКО 2-ALKYLAMINO-3-ARYLSULFONYLCYCLOALCANO[e OR d]PYRAZOLO[1,5-a]PYRIMIDINES - ANTAGONISTS OF SEROTONIN 5-HTRECEPTORS, METHODS FOR THE PRODUCTION AND THE USE THEREOF
BRPI0906809A2 (en) 2008-01-25 2015-07-14 High Point Pharmaceuticals Llc Tricyclic compounds as modulators of tnf- (alpha) synthesis and as inhibitors of pde4.
ES2494365T3 (en) 2008-01-30 2014-09-15 Genentech, Inc. Pyrazolopyrimidine compounds that inhibit PI3K and methods of use
JP2011511005A (en) 2008-02-04 2011-04-07 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド 2-aminopyridine kinase inhibitor
JP2011513233A (en) 2008-02-22 2011-04-28 アイアールエム・リミテッド・ライアビリティ・カンパニー Compounds and compositions as GPR119 activity modulators
EP2257541B1 (en) 2008-02-22 2013-08-14 F. Hoffmann-La Roche AG Modulators for amyloid beta
EP2265588B1 (en) 2008-02-27 2013-06-26 Vitae Pharmaceuticals, Inc. INHIBITORS OF 11ß -HYDROXYSTEROID DEHYDROGENASE TYPE 1
WO2009108827A1 (en) 2008-02-29 2009-09-03 Wyeth Fused tricyclic pyrazolo[1, 5-a]pyrimidines, methods for preparation and uses thereof
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
GB0804701D0 (en) 2008-03-13 2008-04-16 Amura Therapeutics Ltd Compounds
US8637542B2 (en) 2008-03-14 2014-01-28 Intellikine, Inc. Kinase inhibitors and methods of use
WO2009114874A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Benzothiazole kinase inhibitors and methods of use
WO2009146034A2 (en) 2008-03-31 2009-12-03 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
US20100056524A1 (en) 2008-04-02 2010-03-04 Mciver Edward Giles Compound
US8436005B2 (en) 2008-04-03 2013-05-07 Abbott Laboratories Macrocyclic pyrimidine derivatives
WO2009126584A1 (en) 2008-04-07 2009-10-15 Amgen Inc. Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
WO2009124755A1 (en) 2008-04-08 2009-10-15 European Molecular Biology Laboratory (Embl) Compounds with novel medical uses and method of identifying such compounds
WO2009125808A1 (en) 2008-04-11 2009-10-15 第一三共株式会社 Aminocyclohexyl derivative
WO2009125809A1 (en) 2008-04-11 2009-10-15 第一三共株式会社 Piperidine derivatives
EP2444403A1 (en) 2008-04-18 2012-04-25 Shionogi Co., Ltd. Heterocyclic compound having inhibitory activity on PI3K
CN103224497A (en) 2008-04-22 2013-07-31 波托拉医药品公司 Inhibitors of protein kinases
US8309577B2 (en) 2008-04-23 2012-11-13 Bristol-Myers Squibb Company Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands
US7863291B2 (en) 2008-04-23 2011-01-04 Bristol-Myers Squibb Company Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands
NZ609066A (en) 2008-04-29 2014-07-25 Novartis Ag Methods of monitoring the modulation of the kinase activity of fibroblast growth factor receptor and uses of said methods
WO2009132980A1 (en) 2008-04-29 2009-11-05 F. Hoffmann-La Roche Ag Pyrimidinyl pyridone inhibitors of jnk.
WO2009133127A1 (en) 2008-04-30 2009-11-05 Merck Serono S.A. Fused bicyclic compounds and use thereof as pi3k inhibitors
US9315449B2 (en) 2008-05-15 2016-04-19 Duke University Substituted pyrazoles as heat shock transcription factor activators
EP2282995B1 (en) 2008-05-23 2015-08-26 Novartis AG Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors
WO2009144205A1 (en) 2008-05-30 2009-12-03 Basf Se Rylene-based semiconductor materials and methods of preparation and use thereof
CA2726317A1 (en) 2008-06-03 2009-12-10 Merck Sharp & Dohme Corp. Inhibitors of akt activity
CN102089403A (en) 2008-06-10 2011-06-08 巴斯夫欧洲公司 Novel transition metal complex and use thereof in organic light-emitting diodes - III
WO2009151997A1 (en) 2008-06-12 2009-12-17 Merck & Co., Inc. Process for producing bicycloaniline derivatives
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
CN102123989A (en) 2008-06-19 2011-07-13 阿斯利康(瑞典)有限公司 Pyrazole compounds 436
JPWO2009157423A1 (en) 2008-06-24 2011-12-15 財団法人乙卯研究所 Oxazolidinone derivatives having fused rings
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
AU2009271019A1 (en) 2008-07-14 2010-01-21 Gilead Sciences, Inc. Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases
EP2307413B1 (en) 2008-07-15 2015-09-09 F. Hoffmann-La Roche AG Novel phenyl-imidazopyridines and pyridazines
WO2010007099A1 (en) 2008-07-15 2010-01-21 Cellzome Limited 2-aminoimidazo[1,2-b]pyridazine derivatives as pi3k inhibitors
AU2009270971A1 (en) 2008-07-16 2010-01-21 Schering Corporation Bicyclic Heterocycle Derivatives and use thereof as GPR119 modulators
UY31982A (en) 2008-07-16 2010-02-26 Boehringer Ingelheim Int DERIVATIVES OF 1,2-DIHYDROPIRIDIN-3-CARBOXAMIDS N-SUBSTITUTED
JP2011528368A (en) 2008-07-16 2011-11-17 シェーリング コーポレイション Bicyclic heterocyclic derivatives and their use as GPCR modulators
WO2010009735A2 (en) 2008-07-23 2010-01-28 Dako Denmark A/S Combinatorial analysis and repair
EP2320907A4 (en) 2008-08-05 2012-09-05 Merck Sharp & Dohme Therapeutic compounds
WO2010015643A1 (en) 2008-08-06 2010-02-11 Novartis Ag New antiviral modified nucleosides
JP2011530596A (en) 2008-08-11 2011-12-22 プレジデント アンド フェロウズ オブ ハーバード カレッジ Halofuginone analogs and their use for inhibition of tRNA synthetase
UY32049A (en) 2008-08-14 2010-03-26 Takeda Pharmaceutical CMET INHIBITORS
ES2412780T3 (en) 2008-09-10 2013-07-12 Mitsubishi Tanabe Pharma Corporation Aromatic compounds of 6-membered ring containing nitrogen and its use
CN102264762B (en) 2008-09-26 2018-03-27 达纳-法伯癌症研究公司 The anti-PD 1 of people, PD L1 and PD L2 antibody and its application
UY32158A (en) 2008-10-03 2010-04-30 Astrazeneca Ab HETEROCICLIC DERIVATIVES AND METHODS OF USE OF THE SAME
WO2010045371A1 (en) 2008-10-15 2010-04-22 Gilead Palo Alto, Inc. Pyrido- and pyrimido (1, 2-a) pyrimidine compounds useful as stearoyl coa desaturase inhibitors
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
UY32203A (en) 2008-10-29 2010-05-31 Astrazeneca Ab AMINO PIRIMIDINAS AND ITS USE IN THERAPY
US8476282B2 (en) 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
WO2010052448A2 (en) 2008-11-05 2010-05-14 Ucb Pharma S.A. Fused pyrazine derivatives as kinase inhibitors
WO2010059552A1 (en) 2008-11-18 2010-05-27 Glaxosmithkline Llc Prolyl hydroxylase inhibitors
EP2362775B1 (en) 2008-11-20 2015-08-05 GlaxoSmithKline LLC Chemical compounds
JP5522053B2 (en) 2008-12-03 2014-06-18 コニカミノルタ株式会社 ORGANIC ELECTROLUMINESCENT ELEMENT, ORGANIC ELECTROLUMINESCENT ELEMENT MATERIAL, DISPLAY DEVICE AND LIGHTING DEVICE
KR101061599B1 (en) 2008-12-05 2011-09-02 한국과학기술연구원 Novel indazole derivatives that are protein kinase inhibitors for the treatment of abnormal cell growth diseases, pharmaceutically acceptable salts thereof, and pharmaceutical compositions containing the same as active ingredients
KR101805754B1 (en) 2008-12-08 2017-12-07 먼디파머 인터내셔널 코포레이션 리미티드 Compositions of protein receptor tyrosine kinase inhibitors
US8110265B2 (en) 2008-12-09 2012-02-07 The Coca-Cola Company Pet container and compositions having enhanced mechanical properties and gas barrier properties
TWI686405B (en) 2008-12-09 2020-03-01 建南德克公司 Anti-pd-l1 antibodies and their use to enhance t-cell function
EP2376494A4 (en) 2008-12-12 2012-07-11 Msd Kk Dihydropyrimidopyrimidine derivatives
WO2010067886A1 (en) 2008-12-12 2010-06-17 Banyu Pharmaceutical Co.,Ltd. Dihydropyrimidopyrimidine derivative
RU2525116C2 (en) 2008-12-19 2014-08-10 Дженентек, Инк. Heterocyclic compounds and methods of application
JO2885B1 (en) 2008-12-22 2015-03-15 ايلي ليلي اند كومباني Protein kinase inhibitors
JP5739820B2 (en) 2008-12-30 2015-06-24 アークル インコーポレイテッド Substituted 5,6-dihydro-6-phenylbenzo [f] isoquinolin-2-amine compounds
AU2009335016A1 (en) 2008-12-30 2011-08-18 Arqule, Inc. Substituted pyrazolo [3, 4-b] pyridine compounds
WO2010080712A2 (en) 2009-01-06 2010-07-15 Dana Farber Cancer Institute Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
JOP20190231A1 (en) 2009-01-15 2017-06-16 Incyte Corp Processes for preparing jak inhibitors and related intermediate compounds
WO2010083145A1 (en) 2009-01-16 2010-07-22 Merck Sharp & Dohme Corp. IMIDAZO[1,2-a]PYRIDINES AND IMIDAZO[1,2-b]PYRIDAZINES AS MARK INHIBITORS
DE102009007038A1 (en) 2009-02-02 2010-08-05 Merck Patent Gmbh metal complexes
JP2010180147A (en) 2009-02-04 2010-08-19 Mitsubishi Gas Chemical Co Inc Cyanic acid ester compound and cured product thereof
EP3192811A1 (en) 2009-02-09 2017-07-19 Université d'Aix-Marseille Pd-1 antibodies and pd-l1 antibodies and uses thereof
TW201038569A (en) 2009-02-16 2010-11-01 Abbott Gmbh & Co Kg Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
TW201035102A (en) 2009-03-04 2010-10-01 Gruenethal Gmbh Sulfonylated tetrahydroazolopyrazines and their use as medicinal products
WO2010103306A1 (en) 2009-03-10 2010-09-16 Astrazeneca Uk Limited Benzimidazole derivatives and their use as antivaral agents
WO2010104047A1 (en) 2009-03-11 2010-09-16 国立大学法人京都大学 Polycyclic aromatic compound
AR076126A1 (en) 2009-03-18 2011-05-18 Schering Corp BICYCLE COMPOUNDS AS INHIBITORS OF DIACILGLICEROL ACILTRANSFERASA
WO2010111303A2 (en) 2009-03-23 2010-09-30 Siemens Medical Solutions Usa, Inc. Imaging agents for detecting neurological disorders
EP2411370B1 (en) 2009-03-27 2015-04-22 AbbVie Inc. Compounds as cannabinoid receptor ligands
WO2010117425A1 (en) 2009-03-31 2010-10-14 Biogen Idec Ma Inc. Certain substituted pyrimidines, pharmaceutical compositions thereof, and methods for their use
CA2756568C (en) 2009-04-06 2018-02-13 University Health Network Kinase inhibitors and method of treating cancer with same
CN102459246B (en) 2009-04-07 2014-05-07 阿斯利康(瑞典)有限公司 isoxazole-3(2H)-one analog as therapeutical agent
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
JP5531446B2 (en) 2009-04-20 2014-06-25 コニカミノルタ株式会社 ORGANIC ELECTROLUMINESCENT ELEMENT, ORGANIC ELECTROLUMINESCENT ELEMENT MATERIAL, DISPLAY DEVICE AND LIGHTING DEVICE
ES2347630B1 (en) 2009-04-29 2011-09-08 Universitat Ramon Llull SYNTHESIS AND USES OF 4-CIANOPENTANOATOS AND 4-CIANOPENTENOATS SUBSTITUTED.
US8765754B2 (en) 2009-04-29 2014-07-01 Locus Pharmaceuticals, Inc. Pyrrolotriazine compounds
WO2010127212A1 (en) 2009-04-30 2010-11-04 Forest Laboratories Holdings Limited Inhibitors of acetyl-coa carboxylase
US9616244B2 (en) 2009-05-01 2017-04-11 Heartsine Technologies Limited External defibrillator
AR078411A1 (en) 2009-05-07 2011-11-09 Lilly Co Eli IMIDAZOLIL VINYL COMPOUND AND PHARMACEUTICAL COMPOSITION THAT INCLUDES IT
JP5600891B2 (en) 2009-05-15 2014-10-08 コニカミノルタ株式会社 Organic electroluminescence element, display device and lighting device
JP5604808B2 (en) 2009-05-20 2014-10-15 コニカミノルタ株式会社 Organic electroluminescence element, display device and lighting device
JP5568889B2 (en) 2009-05-22 2014-08-13 コニカミノルタ株式会社 ORGANIC ELECTROLUMINESCENT ELEMENT, DISPLAY DEVICE, LIGHTING DEVICE, AND ORGANIC ELECTROLUMINESCENT ELEMENT MATERIAL
JP5629980B2 (en) 2009-05-22 2014-11-26 コニカミノルタ株式会社 Organic electroluminescence element, display device and lighting device
JP5499519B2 (en) 2009-05-27 2014-05-21 コニカミノルタ株式会社 Organic electroluminescence element, display device and lighting device
WO2010136031A1 (en) 2009-05-27 2010-12-02 Københavns Universitet Fibroblast growth factor receptor-derived peptides binding to ncam
GB0910003D0 (en) 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
JP5600894B2 (en) 2009-06-24 2014-10-08 コニカミノルタ株式会社 White organic electroluminescence element, display device and lighting device
HRP20171415T4 (en) 2009-06-25 2023-03-03 Alkermes Pharma Ireland Limited Heterocyclic compounds for the treatment of neurological and psychological disorders
EP2450348B1 (en) 2009-06-30 2016-12-14 Zeon Corporation Novel diarylamine compound, and anti-aging agent, polymer composition, crosslinked rubber product and molded article thereof, and method for producing diarylamine compound
US20120135997A1 (en) 2009-07-17 2012-05-31 Shionogi & Co., Ltd. Pharmaceutical composition comprising a lactam or benzenesulfonamide compound
WO2011011597A1 (en) 2009-07-24 2011-01-27 Duke University Prochelators useful for inhibiting metal-associated toxicity
FR2948568B1 (en) 2009-07-30 2012-08-24 Sanofi Aventis PHARMACEUTICAL FORMULATION
TWI468402B (en) 2009-07-31 2015-01-11 必治妥美雅史谷比公司 Compounds for the reduction of β-amyloid production
MX2012001504A (en) 2009-08-05 2012-06-01 Versitech Ltd Antiviral compounds and methods of making and using there of cross reference to related applications.
JP2012197231A (en) 2009-08-06 2012-10-18 Oncotherapy Science Ltd Pyridine and pyrimidine derivative having ttk-inhibiting action
DK2471786T3 (en) 2009-08-07 2016-01-25 Chugai Pharmaceutical Co Ltd aminopyrazole derivative
WO2011018894A1 (en) 2009-08-10 2011-02-17 Raqualia Pharma Inc. Pyrrolopyrimidine derivatives as potassium channel modulators
JP5819831B2 (en) 2009-08-17 2015-11-24 インテリカイン， エルエルシー Heterocyclic compounds and their use
JP5577650B2 (en) 2009-08-24 2014-08-27 コニカミノルタ株式会社 ORGANIC ELECTROLUMINESCENT ELEMENT, ORGANIC ELECTROLUMINESCENT ELEMENT MATERIAL, DISPLAY DEVICE AND LIGHTING DEVICE
KR101184115B1 (en) 2009-08-31 2012-09-18 일동제약주식회사 New peptide deformylase inhibitor compounds and the manufacturing process thereof
EA021275B9 (en) 2009-09-03 2015-08-31 Байоэнердженикс Heterocyclic compounds, pharmaceutical composition comprising same and use thereof for treatment of pask-mediated disease
CA2772790C (en) 2009-09-04 2017-06-27 Benjamin Bader Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
WO2011031740A1 (en) 2009-09-09 2011-03-17 Achaogen, Inc. Antibacterial fluoroquinolone analogs
EP2475666A2 (en) 2009-09-11 2012-07-18 Trius Therapeutics, Inc. Gyrase inhibitors
EP2483275B1 (en) 2009-10-01 2014-10-15 Merck Sharp & Dohme Corp. HETEROCYCLIC-FUSED PYRAZOLO[4,3-c]PYRIDIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
US8466155B2 (en) 2009-10-02 2013-06-18 Boehringer Ingelheim International Gmbh Pyrimidines
GB0917571D0 (en) 2009-10-07 2009-11-25 Karobio Ab Novel estrogen receptor ligands
EP2308866A1 (en) 2009-10-09 2011-04-13 Bayer CropScience AG Phenylpyri(mi)dinylpyrazoles and their use as fungicides
FR2951172B1 (en) 2009-10-13 2014-09-26 Pf Medicament PYRAZOLOPYRIDINE DERIVATIVES AS ANTI-CANCER AGENT
EP2491033A4 (en) 2009-10-20 2013-03-13 Eiger Biopharmaceuticals Inc Azaindazoles to treat flaviviridae virus infection
KR20110043270A (en) 2009-10-21 2011-04-27 (주)씨에스엘쏠라 Organic light emitting compound and organic light emitting device comprising the same
KR101793300B1 (en) 2009-10-22 2017-11-02 길리애드 사이언시즈, 인코포레이티드 Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections
WO2011050245A1 (en) 2009-10-23 2011-04-28 Yangbo Feng Bicyclic heteroaryls as kinase inhibitors
WO2011053518A1 (en) 2009-10-26 2011-05-05 Signal Pharmaceuticals, Llc Methods of synthesis and purification of heteroaryl compounds
US20120220600A1 (en) 2009-10-30 2012-08-30 Reiner Aichholz N-Oxide of 3-(2,6-dichloro-3,5-dimethoxy-phenyl) -1--1-methyl-urea
KR20110049217A (en) 2009-11-04 2011-05-12 다우어드밴스드디스플레이머티리얼 유한회사 Novel organic electroluminescent compounds and organic electroluminescent device using the same
GB0919432D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
NZ629615A (en) 2009-11-06 2016-01-29 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
US8629132B2 (en) 2009-11-13 2014-01-14 Genosco Kinase inhibitors
CN105906631A (en) 2009-11-18 2016-08-31 普莱希科公司 Compounds and methods for kinase modulation, and indications therefor
JP2013032290A (en) 2009-11-20 2013-02-14 Dainippon Sumitomo Pharma Co Ltd Novel fused pyrimidine derivative
US20120232073A1 (en) 2009-11-23 2012-09-13 Santhosh Francis Neelamkavil Fused bicyclic pyrimidine derivatives and methods of use thereof
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc Simultaneous inhibition of pd-l1/pd-l2
EP2332939A1 (en) * 2009-11-26 2011-06-15 Æterna Zentaris GmbH Novel Naphthyridine derivatives and the use thereof as kinase inhibitors
SG181147A1 (en) 2009-12-01 2012-07-30 Abbott Lab Novel tricyclic compounds
JP2011116840A (en) 2009-12-02 2011-06-16 Fujifilm Corp Pigment fine particle dispersion, photocurable composition using the same, and color filter
AR079257A1 (en) 2009-12-07 2012-01-04 Novartis Ag CRYSTAL FORMS OF 3- (2,6-DICLORO-3-5-DIMETOXI-PHENYL) -1- {6- [4- (4-ETIL-PIPERAZIN-1-IL) -PENYL-AMINO] -PIRIMIDIN-4- IL} -1-METHYL-UREA AND SALTS OF THE SAME
SG181803A1 (en) 2009-12-17 2012-07-30 Merck Sharp & Dohme Aminopyrimidines as syk inhibitors
WO2011075620A1 (en) 2009-12-18 2011-06-23 Novartis Ag Method for treating haematological cancers
MX350761B (en) 2009-12-22 2017-09-18 Vertex Pharma Isoindolinone inhibitors of phosphatidylinositol 3-kinase.
FR2954315B1 (en) 2009-12-23 2012-02-24 Galderma Res & Dev NOVEL PHENOLIC DERIVATIVES, AND THEIR PHARMACEUTICAL OR COSMETIC USE
FR2954317B1 (en) 2009-12-23 2012-01-27 Galderma Res & Dev NOVEL PHENOLIC DERIVATIVES, AND THEIR PHARMACEUTICAL OR COSMETIC USE
WO2011079231A1 (en) 2009-12-23 2011-06-30 Gatekeeper Pharmaceutical, Inc. Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
US20130096115A1 (en) 2009-12-28 2013-04-18 Afraxis, Inc. Methods for treating autism
WO2011080755A1 (en) 2009-12-29 2011-07-07 Advinus Therapeutics Private Limited Fused nitrogen heterocyclic compounds, process of preparation and uses thereof
CA2784807C (en) 2009-12-29 2021-12-14 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
CN102933581A (en) 2009-12-29 2013-02-13 破立纪元有限公司 Thionated aromatic bisimides as organic semiconductors and devices incorporating them
WO2011082266A2 (en) 2009-12-30 2011-07-07 Arqule, Inc. Substituted heterocyclic compounds
AU2010339444A1 (en) 2009-12-30 2012-07-19 Arqule, Inc. Substituted pyrrolo-aminopyrimidine compounds
US8329705B2 (en) 2009-12-30 2012-12-11 Arqule, Inc. Substituted triazolo-pyrazine compounds
CN102115026A (en) 2009-12-31 2011-07-06 清华大学 One-dimensional nano-structure, preparation method thereof and method for marking by using one-dimensional nano-structure
US20130022629A1 (en) 2010-01-04 2013-01-24 Sharpe Arlene H Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof
AR079975A1 (en) 2010-01-06 2012-03-07 British Columbia Cancer Agency THERAPEUTIC AGENTS DERIVED FROM BISPHENOL OR METHODS FOR USE, PHARMACEUTICAL COMPOSITIONS AND USE OF THE SAME
KR101483215B1 (en) 2010-01-29 2015-01-16 한미약품 주식회사 Bicyclic heteroaryl derivatives having inhibitory activity for protein kinases
WO2011094890A1 (en) 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
CA2789344A1 (en) 2010-02-15 2011-08-18 Jeremy Earle Wulff Synthesis of bicyclic compounds and method for their use as therapeutic agents
CA2789711C (en) 2010-02-17 2014-08-05 Amgen Inc. Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain
SA111320200B1 (en) 2010-02-17 2014-02-16 ديبيوفارم اس ايه Bicyclic Compounds and their Uses as Dual C-SRC / JAK Inhibitors
US9433621B2 (en) 2010-02-18 2016-09-06 Merck Sharp & Dohme Corp. Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
WO2011102441A1 (en) 2010-02-18 2011-08-25 Ntn株式会社 Thickener, grease, method for producing thickener, method for producing grease, and greased bearing
WO2011103460A1 (en) 2010-02-18 2011-08-25 Medivation Technologies, Inc. Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]ondole derivatives and methods of use
UY33227A (en) 2010-02-19 2011-09-30 Novartis Ag PIRROLOPIRIMIDINE COMPOUNDS AS INHIBITORS OF THE CDK4 / 6
WO2011103557A1 (en) 2010-02-22 2011-08-25 Advanced Cancer Therapeutics, Llc Small molecule inhibitors of pfkfb3 and glycolytic flux and their methods of use as anti-cancer therapeutics
CN102770981B (en) 2010-02-26 2015-05-13 新日铁住金化学株式会社 Organic electroluminescent element
WO2011109237A2 (en) 2010-03-02 2011-09-09 Emory University Uses of noscapine and derivatives in subjects diagnosed with fap
WO2011111880A1 (en) 2010-03-08 2011-09-15 주식회사 메디젠텍 Pharmaceutical composition for treating or preventing diseases caused by the nuclear export of gsk3, including a compound for inhibiting the nuclear export of gsk3
WO2011112687A2 (en) 2010-03-10 2011-09-15 Kalypsys, Inc. Heterocyclic inhibitors of histamine receptors for the treatment of disease
US9562056B2 (en) 2010-03-11 2017-02-07 Gilead Connecticut, Inc. Imidazopyridines Syk inhibitors
JP2013522292A (en) 2010-03-16 2013-06-13 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Indazole compounds and their use
CN102884060B (en) 2010-03-24 2019-07-19 阿米泰克治疗方案公司 For inhibiting the heterocyclic compound of kinases
WO2011123493A1 (en) 2010-03-31 2011-10-06 Bristol-Myers Squibb Company Substituted pyrrolotriazines as protein kinase inhibitors
CN102153551B (en) 2010-04-02 2012-04-25 济南海乐医药技术开发有限公司 Indazole/azaindazole-based diarylcarbamide/thiocarbamide-structure antineoplastic drug
JP5724204B2 (en) 2010-04-07 2015-05-27 コニカミノルタ株式会社 Organic electroluminescence element, display device, and lighting device
WO2011130390A1 (en) 2010-04-13 2011-10-20 Rigel Pharmaceuticals, Inc. 2, 4-pyrimidinediamine compounds and prodrugs thereof and their uses
CA2793779A1 (en) 2010-04-16 2011-10-20 Novartis Ag Organic compound for use in the treatment of liver cancer
ES2545811T3 (en) 2010-04-22 2015-09-16 Janssen Pharmaceutica Nv Indazole compounds useful as ketohexokinase inhibitors
AR081331A1 (en) 2010-04-23 2012-08-08 Cytokinetics Inc AMINO- PYRIMIDINES COMPOSITIONS OF THE SAME AND METHODS FOR THE USE OF THE SAME
MX2012012353A (en) 2010-04-23 2013-02-07 Kineta Inc Anti-viral compounds.
EP2563796B1 (en) 2010-04-30 2015-03-18 Bristol-Myers Squibb Company Aza-bicyclic amine n-oxide compounds as alpha-7 nicotinic acetylcholine receptor ligand pro-drugs
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
US8759398B2 (en) 2010-05-03 2014-06-24 Biolink Life Sciences, Inc. Phosphorus binder composition for treatment of hyperphosphatemia
US20130137709A1 (en) 2010-05-05 2013-05-30 Nathanael S. Gray Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith
JP2013529076A (en) 2010-05-11 2013-07-18 アベオ ファーマシューティカルズ， インコーポレイテッド Anti-FGFR2 antibody
JP2013528598A (en) 2010-05-11 2013-07-11 ファイザー・インク Morpholine compounds as mineralocorticoid receptor antagonists
TWI513694B (en) 2010-05-11 2015-12-21 Amgen Inc Pyrimidine compounds that inhibit anaplastic lymphoma kinase
CA2799154A1 (en) 2010-05-12 2011-11-17 Abbvie Inc. Indazole inhibitors of kinase
WO2011143475A1 (en) 2010-05-12 2011-11-17 Spectrum Pharmaceuticals, Inc. Lanthanum carbonate hydroxide, lanthanum oxycarbonate and methods of their manufacture and use
GB201008134D0 (en) 2010-05-14 2010-06-30 Medical Res Council Technology Compounds
WO2011147199A1 (en) 2010-05-28 2011-12-01 Versitech Limited Compounds and methods for treating viral infections
WO2011147198A1 (en) 2010-05-28 2011-12-01 Versitech Limited Compounds and methods for treatment of proliferative diseases
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
MA34299B1 (en) 2010-06-04 2013-06-01 Hoffmann La Roche AMINOPYRIMIDINE DERIVATIVES AS MODULATORS OF LRRK2
WO2011155983A1 (en) 2010-06-07 2011-12-15 Bikam Pharmaceuticals Inc. Opsin-binding ligands, compositions and methods of use
TW201210597A (en) 2010-06-09 2012-03-16 Gilead Sciences Inc Inhibitors of hepatitis C virus
US8299117B2 (en) 2010-06-16 2012-10-30 Metabolex Inc. GPR120 receptor agonists and uses thereof
WO2011159877A2 (en) 2010-06-18 2011-12-22 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
EP2584903B1 (en) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
KR101486782B1 (en) 2010-06-27 2015-01-28 킹 사우드 유니버시티 One-time password authentication with infinite nested hash chains
CA2803446C (en) 2010-07-02 2019-06-04 University Health Network Use of plk4 antagonists for treating pten mutant diseases
WO2012004217A1 (en) 2010-07-06 2012-01-12 Novartis Ag Cyclic ether compounds useful as kinase inhibitors
FR2962438B1 (en) 2010-07-06 2012-08-17 Sanofi Aventis INDOLIZINE DERIVATIVES, PREPARATION METHODS AND THERAPEUTIC APPLICATION
FR2962437B1 (en) 2010-07-06 2012-08-17 Sanofi Aventis IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARING THEM AND THEIR THERAPEUTIC APPLICATION
EP2590982B1 (en) 2010-07-09 2017-08-23 The Walter and Eliza Hall Institute of Medical Research Protein kinase inhibitors and methods of treatment
WO2012009258A2 (en) 2010-07-13 2012-01-19 Edward Roberts Peptidomimetic galanin receptor modulators
US20130210807A1 (en) 2010-07-14 2013-08-15 Nigel J Liverton Tricyclic Compounds as Allosteric Modulators of Metabotropic Glutamate Receptors.
TW201206946A (en) 2010-07-15 2012-02-16 Bristol Myers Squibb Co Compounds for the reduction of beta-amyloid production
EP2594566A4 (en) 2010-07-16 2014-10-01 Kyowa Hakko Kirin Co Ltd Nitrogenated aromatic heterocyclic ring derivative
WO2012008564A1 (en) 2010-07-16 2012-01-19 協和発酵キリン株式会社 Nitrogenated aromatic heterocyclic ring derivative
EP2598505B1 (en) 2010-07-28 2015-03-18 Bayer Intellectual Property GmbH Substituted imidazo[1,2-b]pyridazines
EP2413140A1 (en) 2010-07-29 2012-02-01 Sanofi Method for identifying a compound having an antiarrhythmic effect as well as uses relating thereto
US20140054564A1 (en) 2010-07-30 2014-02-27 Rohm And Haas Electronic Materials Korea Ltd. Electroluminescent device using electroluminescent compound as luminescent material
US8906943B2 (en) 2010-08-05 2014-12-09 John R. Cashman Synthetic compounds and methods to decrease nicotine self-administration
US8883839B2 (en) 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
EP2608669B1 (en) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
WO2012027239A1 (en) 2010-08-23 2012-03-01 Schering Corporation NOVEL PYRAZOLO[1,5-a]PYRROLO[3,2-e]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
EP2611798B1 (en) 2010-09-01 2015-04-08 Gilead Connecticut, Inc. Pyridazinones, method of making, and method of use thereof
ES2561277T3 (en) 2010-09-01 2016-02-25 Gilead Connecticut, Inc. Pyridinones / pyrazinones, procedure of preparation and procedure of use of the same
US9326987B2 (en) 2010-09-08 2016-05-03 Glaxo Group Limited Indazole derivatives for use in the treatment of influenza virus infection
HUE026059T2 (en) 2010-09-08 2016-05-30 Glaxosmithkline Ip Dev Ltd POLYMORPHS AND SALTS OF N-[5-[4-(5-{[(2R,6S)-2,6-DIMETHYL-4-MORPHOLINYL]METHYL}-& xA;1,3-OXAZOL-2-YL)-1H-INDAZOL-6-YL]-2-(METHYLOXY)-3-PYRIDINYL]METHANESULFONAMIDE
AR082799A1 (en) 2010-09-08 2013-01-09 Ucb Pharma Sa DERIVATIVES OF QUINOLINE AND QUINOXALINE AS QUINASE INHIBITORS
TWI541243B (en) 2010-09-10 2016-07-11 拜耳知識產權公司 Substituted imidazopyridazines
US8900785B2 (en) 2010-09-14 2014-12-02 Hodogaya Chemical Co., Ltd. Charge control agent and toner using the same
CN102399233B (en) 2010-09-15 2014-08-13 山东轩竹医药科技有限公司 Dual PI3K and mTOR inhibitor compounds
CN102399220A (en) 2010-09-15 2012-04-04 黄振华 Tricyclic dual PI3K and mTOR inhibitors
WO2012036233A1 (en) 2010-09-17 2012-03-22 塩野義製薬株式会社 Condensed heterocyclic derivative having melanine-concentrating hormone receptor antagonistic activity
GB201015949D0 (en) 2010-09-22 2010-11-03 Medical Res Council Technology Compounds
JO3062B1 (en) 2010-10-05 2017-03-15 Lilly Co Eli Crystalline (r)-(e)-2-(4-(2-(5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1h-indazol-3-yl)vinyl)-1h-pyrazol-1-yl)ethanol
WO2012054364A2 (en) 2010-10-22 2012-04-26 Merck Sharp & Dohme Corp. Bicyclic diamines as janus kinase inhibitors
RU2621674C2 (en) 2010-10-25 2017-06-07 Г1 Терапьютикс Инк., Inhibitors of cdk
JP2012092049A (en) 2010-10-27 2012-05-17 Sumitomo Chemical Co Ltd Pest control composition and method for controlling pest
CA2816022C (en) 2010-10-29 2019-09-10 Emory University Quinazoline derivatives, compositions, and uses related thereto
WO2012061337A1 (en) 2010-11-02 2012-05-10 Exelixis, Inc. Fgfr2 modulators
US9242970B2 (en) 2010-11-10 2016-01-26 Actelion Pharmaceuticals Ltd. Lactam derivatives useful as orexin receptor antagonists
US20120115903A1 (en) 2010-11-10 2012-05-10 Gruenenthal Gmbh Substituted Heteroaromatic Carboxamide and Urea Compounds as Vanilloid Receptor Ligands
JP2012116825A (en) 2010-11-11 2012-06-21 Ehime Univ Method for producing acene diimide compound
KR101171232B1 (en) 2010-11-15 2012-08-06 단국대학교 산학협력단 Spiro Compound and Organic Light Emitting Device Including the Same
WO2012065297A1 (en) 2010-11-16 2012-05-24 Impact Therapeutics, Inc. 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF
CA2816144A1 (en) 2010-11-17 2012-05-24 Amgen Inc. Quinoline derivatives as pik3 inhibitors
CA2818389A1 (en) 2010-11-18 2012-05-24 Kasina Laila Innova Pharmaceuticals Private Limited Substituted 4-(selenophen-2(or 3)-ylamino)pyrimidine compounds and methods of use thereof
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
EP2796456A1 (en) 2010-12-09 2014-10-29 Amgen Inc. Bicyclic compounds as Pim inhibitors
DK2835131T3 (en) 2010-12-14 2017-12-04 Electrophoretics Ltd Casein kinase 1 delta inhibitors (CK1 delta)
US9073892B2 (en) 2010-12-20 2015-07-07 Merck Serono S.A. Indazolyl triazol derivatives
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
EP2655312A1 (en) 2010-12-22 2013-10-30 Leo Laboratories Limited 3-acyl-ingenols ii
TWI591047B (en) 2010-12-22 2017-07-11 理奧實驗有限公司 Ingenol-3-acylates iii and ingenol-3-carbamates
EP2468258A1 (en) 2010-12-22 2012-06-27 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising a low soluble pharmaceutically active ingredient
CN102603628B (en) 2010-12-22 2016-08-17 香港理工大学 Quinoline as antitumor and anticancer agent
CA2822590A1 (en) 2010-12-23 2012-06-28 Amgen Inc. Heterocyclic compounds and their uses
JP5691508B2 (en) 2010-12-27 2015-04-01 Jnc株式会社 Diimide compound and inkjet ink and use thereof
KR101466150B1 (en) 2010-12-31 2014-11-27 제일모직 주식회사 Compound for organic photoelectric device and organic photoelectric device including the same
WO2012093731A1 (en) 2011-01-06 2012-07-12 Ｊｘ日鉱日石エネルギー株式会社 Imide compound, method for producing same, thickening agent for grease, and grease composition
US8362023B2 (en) 2011-01-19 2013-01-29 Hoffmann-La Roche Inc. Pyrazolo pyrimidines
FR2970967B1 (en) 2011-01-27 2013-02-15 Pf Medicament AZAINDAZOLE OR DIAZAINDAZOLE DERIVATIVES AS A MEDICINAL PRODUCT
EP2487159A1 (en) 2011-02-11 2012-08-15 MSD Oss B.V. RorgammaT inhibitors
WO2012112965A1 (en) 2011-02-18 2012-08-23 Medivation Technologies, Inc. Compounds and methods of treating diabetes
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
TWI532742B (en) 2011-02-28 2016-05-11 艾伯維有限公司 Tricyclic inhibitors of kinases
CN103429759A (en) 2011-03-17 2013-12-04 诺华股份有限公司 FGFR and ligands thereof as biomarkers for breast cancer in HR positive subjects
WO2012129344A1 (en) 2011-03-23 2012-09-27 Amgen Inc. Fused tricyclic dual inhibitors of cdk 4/6 and flt3
ITPD20110091A1 (en) 2011-03-24 2012-09-25 Univ Padova USEFUL INHIBITORS FOR RELATED PATHOLOGIES: PHARMACOFORIC MODELS, IDENTIFIED COMPOUNDS BY THESE MODELS, METHODS FOR THEIR PREPARATION, THEIR FORMULATION AND THEIR THERAPEUTIC USE.
TW201302681A (en) 2011-03-25 2013-01-16 Abbott Lab TRPV1 antagonists
JP2014516511A (en) 2011-04-07 2014-07-17 ジェネンテック， インコーポレイテッド Anti-FGFR4 antibody and method of use
FR2974088A1 (en) 2011-04-12 2012-10-19 Pf Medicament TRI- AND TETRACYCLIC PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS AS ANTI-CANCER AGENTS
ES2628385T3 (en) 2011-05-16 2017-08-02 F. Hoffmann-La Roche Ag FGFR1 agonists and use procedures
US9376438B2 (en) 2011-05-17 2016-06-28 Principia Biopharma, Inc. Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
US20140288069A1 (en) 2011-05-17 2014-09-25 Bayer Intellectual Property Gmbh Amino-substituted imidazopyridazines as mknk1 kinase inhibitors
KR20140023358A (en) 2011-05-19 2014-02-26 노파르티스 아게 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one for use in the treatment of adenoid cystic carcinoma
EP2714692B1 (en) 2011-06-01 2017-03-22 Bayer Intellectual Property GmbH Substituted aminoimidazopyridazines
TW201316991A (en) 2011-06-03 2013-05-01 Millennium Pharm Inc Combination of MEK inhibitors and selective inhibitors of Aurora A kinase
CN103597053B (en) 2011-06-13 2016-09-21 株式会社Lg化学 Compound and the organic electronic device of this compound of use
CN103764656A (en) 2011-06-22 2014-04-30 拜耳知识产权有限责任公司 Heterocyclyl aminoimidazopyridazines
US8846656B2 (en) 2011-07-22 2014-09-30 Novartis Ag Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators
MX365311B (en) 2011-08-12 2019-05-29 Nissan Chemical Ind Ltd Tricyclic heterocyclic compounds and jak inhibitors.
CA2838784A1 (en) 2011-08-12 2013-02-21 F. Hoffmann-La Roche Ag Pyrazolo[3,4-c]pyridine compounds and methods of use
JP2013049251A (en) 2011-08-31 2013-03-14 Fujifilm Corp Relief printing plate original plate for laser engraving, and, relief printing plate and method for producing the same
WO2013033981A1 (en) 2011-09-06 2013-03-14 江苏先声药物研究有限公司 2,7-naphthyridine derivative, preparation method therefor and use thereof
US9345705B2 (en) 2011-09-15 2016-05-24 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
WO2013041634A1 (en) 2011-09-23 2013-03-28 Bayer Intellectual Property Gmbh Substituted imidazopyridazines
US9376435B2 (en) 2011-09-23 2016-06-28 Jawaharlal Nehru Centre For Advanced Scientific Research Chromophores for the detection of volatile organic compounds
EP2748169A4 (en) 2011-09-30 2015-06-17 Kineta Inc Anti-viral compounds
UA111382C2 (en) 2011-10-10 2016-04-25 Оріон Корпорейшн Protein kinase inhibitors
US20140051679A1 (en) 2011-10-12 2014-02-20 Univeristy Health Networks Kinase inhibitors and method of treating cancer with same
KR101897044B1 (en) 2011-10-20 2018-10-23 에스에프씨 주식회사 Organic metal compounds and organic light emitting diodes comprising the same
WO2013063003A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
KR20140096035A (en) 2011-10-28 2014-08-04 노파르티스 아게 Method of treating gastrointestinal stromal tumors
WO2013088191A1 (en) 2011-12-12 2013-06-20 Institut National De La Sante Et De La Recherche Medicale (Inserm) Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3
FR2985257B1 (en) 2011-12-28 2014-02-14 Sanofi Sa FGFS RECEPTOR AGONISTIC DIMERS (FGFRS), PREPARATION METHOD AND THERAPEUTIC USE THEREOF
FR2985258A1 (en) 2011-12-28 2013-07-05 Sanofi Sa FGFS RECEPTOR AGONISTIC DIMERS (FGFRS), PREPARATION METHOD AND THERAPEUTIC USE THEREOF
US10026905B2 (en) 2012-01-18 2018-07-17 Duk San Neolux Co., Ltd. Compound, organic electric element using the same, and an electronic device thereof
WO2013109027A1 (en) 2012-01-18 2013-07-25 덕산하이메탈(주) Compound, organic electronic element using same and electronic device thereof
AU2013210403B2 (en) 2012-01-19 2016-01-14 Taiho Pharmaceutical Co., Ltd. 3,5-disubstituted alkynylbenzene compound and salt thereof
CA2865021C (en) 2012-02-23 2020-06-30 Bayer Intellectual Property Gmbh Substituted benzothienyl-pyrrolotriazines and uses thereof
JP2013179181A (en) 2012-02-28 2013-09-09 Sumitomo Chemical Co Ltd Organic photoelectric conversion element
JP6431770B2 (en) 2012-03-14 2018-11-28 ルピン・リミテッド Heterocyclyl compounds as MEK inhibitors
MX354783B (en) 2012-03-30 2018-03-21 Novartis Ag Fgfr inhibitor for use in the treatment of hypophosphatemic disorders.
JP5120580B1 (en) 2012-05-14 2013-01-16 Ｊｓｒ株式会社 Liquid crystal alignment agent
AU2013264730B2 (en) 2012-05-20 2018-02-01 Tel Hashomer Medical Research Infrastructure And Services Ltd. Prosthetic mitral valve
PT3176170T (en) 2012-06-13 2019-02-05 Incyte Holdings Corp Substituted tricyclic compounds as fgfr inhibitors
EP2872142A1 (en) 2012-07-11 2015-05-20 Novartis AG Method of treating gastrointestinal stromal tumors
ES2916220T3 (en) 2012-07-11 2022-06-29 Blueprint Medicines Corp Fibroblast growth factor receptor inhibitors
JP2015525782A (en) 2012-08-02 2015-09-07 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Antidiabetic tricyclic compounds
WO2014019186A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
KR101985259B1 (en) 2012-08-10 2019-06-03 제이에스알 가부시끼가이샤 Liquid crystal aligning agent and compound
WO2014044846A1 (en) 2012-09-24 2014-03-27 Evotec (Uk) Ltd. 3-(aryl- or heteroaryl-amino)-7-(3,5-dimethoxyphenyl)isoquinoline derivatives as fgfr inhibitors useful for the treatment of proliferative disorders or dysplasia
WO2014048878A1 (en) 2012-09-26 2014-04-03 Evotec (Uk) Ltd. Phenyl- or pyridyl- pyrrolo[2,3b]pyrazine derivatives useful in the treatment or prevention of proliferative disorders or dysplasia
WO2014062454A1 (en) 2012-10-15 2014-04-24 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
KR102000211B1 (en) 2012-10-29 2019-09-30 삼성디스플레이 주식회사 Organometallic compound and organic light emitting diode comprising the same
US20140148548A1 (en) 2012-11-28 2014-05-29 Central Glass Company, Limited Fluorine-Containing Polymerizable Monomer And Polymer Compound Using Same
AU2013352568B2 (en) 2012-11-28 2019-09-19 Merck Sharp & Dohme Llc Compositions and methods for treating cancer
CN104968664A (en) 2012-12-12 2015-10-07 山东亨利医药科技有限责任公司 Bicyclic compound functioning as tyrosine kinase inhibitor
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
TWI629266B (en) 2012-12-28 2018-07-11 藍印藥品公司 Inhibitors of the fibroblast growth factor receptor
WO2014105849A1 (en) 2012-12-28 2014-07-03 Xoma (Us) Llc Antibodies specific for fgfr4 and methods of use
KR102030587B1 (en) 2013-01-09 2019-10-10 에스에프씨주식회사 Asymmetric antracene derivatives having two naphthyl groups and organic light-emitting diode including the same
WO2014113191A1 (en) 2013-01-15 2014-07-24 Xiaohu Zhang Hedgehog pathway signaling inhibitors and therapeutic applications thereof
CN103694236B (en) 2013-01-15 2017-05-31 苏州开拓药业股份有限公司 A kind of pyrimidine scaffold has the antitumoral compounds of activity of hedgehog path antagonist
KR101456626B1 (en) 2013-02-01 2014-11-03 대영이앤비 주식회사 Apparatus for protecting negative pressure of refrigerator
WO2014136972A1 (en) 2013-03-07 2014-09-12 国立大学法人九州大学 Supramolecular complex, light-emitting body, and sensor element for detecting organic compound
WO2014138485A1 (en) 2013-03-08 2014-09-12 Irm Llc Ex vivo production of platelets from hematopoietic stem cells and the product thereof
WO2014160478A1 (en) 2013-03-13 2014-10-02 Flatley Discovery Lab Compounds and methods for the treatment of cystic fibrosis
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
EP2970258B1 (en) 2013-03-14 2018-04-18 AbbVie Deutschland GmbH & Co KG Novel inhibitor compounds of phosphodiesterase type 10a
TWI647220B (en) 2013-03-15 2019-01-11 美商西建卡爾有限責任公司 Heteroaryl compound and its use
MX2015011514A (en) 2013-03-15 2016-08-11 Celgene Avilomics Res Inc Heteroaryl compounds and uses thereof.
EP2970231A1 (en) 2013-03-15 2016-01-20 Blueprint Medicines Corporation Piperazine derivatives and their use as kit modulators
CA2907243C (en) 2013-03-15 2021-12-28 Celgene Avilomics Research, Inc. Substituted dihydropyrimidopyrimidinone compounds and pharmaceutical compositions thereof use fgfr4 inhibitor
TWI628176B (en) 2013-04-04 2018-07-01 奧利安公司 Protein kinase inhibitors
KR101573611B1 (en) 2013-04-17 2015-12-01 주식회사 엘지화학 Fullerene derivatives, organic solar cell using the same and fabricating method thereof
SG10201708520YA (en) 2013-04-19 2017-12-28 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
BR112015026143A2 (en) 2013-04-19 2017-10-17 Covagen Ag Bispecific and nucleic acid ligand molecules, vector, host cell or non-human host, and pharmaceutical composition
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
EP2994470B1 (en) 2013-05-09 2018-04-18 Principia Biopharma Inc. Pyrido[2,3-d]pyrimidine derivatives as fibroblast growth factor inhibitors
US9572799B2 (en) 2013-06-14 2017-02-21 Sanofi Pyrazolopyridine derivatives for use in the treatment of bladder cancer
US9670231B2 (en) 2013-06-28 2017-06-06 Beigene, Ltd. Fused tricyclic amide compounds as multiple kinase inhibitors
JP6380861B2 (en) 2013-06-28 2018-08-29 ベイジーン リミテッド Condensed tricyclic urea compounds as Raf kinase and / or dimer inhibitors of Raf kinase
BR112016000059B1 (en) 2013-07-02 2020-12-29 Syngenta Participations Ag bi or tricyclic heterocycles compounds, composition comprising said compounds, method for combating and controlling pests, method for protecting plant propagation material from attack by pests and plant propagation material coated with said composition
CA2917667A1 (en) 2013-07-09 2015-01-15 Dana-Farber Cancer Institute, Inc. Kinase inhibitors for the treatment of disease
JP6018547B2 (en) 2013-07-09 2016-11-02 大成ロテック株式会社 Paving machine
NZ715687A (en) 2013-07-11 2019-04-26 Acea Biosciences Inc Pyrimidine derivatives as kinase inhibitors
TW201605452A (en) 2013-08-28 2016-02-16 安斯泰來製藥股份有限公司 Pharmaceutical composition containing pyrimidine compound as an active ingredient
UA116920C2 (en) 2013-10-18 2018-05-25 ЕЙСАЙ Ар ЕНД Ді МЕНЕДЖМЕНТ КО., ЛТД. Pyrimidine fgfr4 inhibitors
PE20160546A1 (en) 2013-10-25 2016-05-26 Novartis Ag BICYCLE PYRIDYL DERIVED COMPOUNDS FUSED TO RING AS INHIBITORS OF FGFR4
ES2924111T3 (en) 2013-10-25 2022-10-04 Blueprint Medicines Corp Fibroblast growth factor receptor inhibitors
FR3012330B1 (en) 2013-10-29 2015-10-23 Oreal BIPHASE COMPOSITION COMPRISING AN ESTER OF FATTY ACID AND SUGAR OR A LIQUID ALKYLPOLYGLUCOSIDE OF HLB <8, AND A C8-C18 BRANCHED ALKANE
WO2015066452A2 (en) 2013-11-01 2015-05-07 Foundation Medicine, Inc. Methods of treating pediatric cancers
US9695165B2 (en) 2014-01-15 2017-07-04 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
US10562900B2 (en) 2014-08-19 2020-02-18 Shanghai Haihe Pharmaceutical Co., Ltd. Indazole compounds as FGFR kinase inhibitor, preparation and use thereof
CN104262330B (en) 2014-08-27 2016-09-14 广东东阳光药业有限公司 A kind of urea substituted biphenyl compounds and combinations thereof thing and purposes
WO2016042084A1 (en) 2014-09-19 2016-03-24 Bayer Pharma Aktiengesellschaft Benzyl substituted indazoles as bub1 inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US20160115164A1 (en) 2014-10-22 2016-04-28 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
AU2016219794A1 (en) 2015-02-20 2017-09-07 Oregon Health & Science University Derivatives of sobetirome
MA41551A (en) 2015-02-20 2017-12-26 Incyte Corp BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS
TWI712601B (en) 2015-02-20 2020-12-11 美商英塞特公司 Bicyclic heterocycles as fgfr inhibitors
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
KR20180014778A (en) 2015-06-03 2018-02-09 트리아스텍 인코포레이티드 Formulations and uses thereof
JP6744394B2 (en) 2015-07-15 2020-08-19 キャボット コーポレイションＣａｂｏｔ Ｃｏｒｐｏｒａｔｉｏｎ Elastomer composites reinforced with silica and products containing the same
LT3322701T (en) 2015-07-15 2019-07-10 F. Hoffmann-La Roche Ag Ethynyl derivatives as metabotropic glutamate receptor modulators
KR102513978B1 (en) 2015-07-15 2023-03-27 프로타고니스트 테라퓨틱스, 인코포레이티드 Peptide inhibitors of the interleukin-23 receptor and their use for the treatment of inflammatory diseases
MY189596A (en) 2015-07-15 2022-02-18 Immatics Biotechnologies Gmbh A novel peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
PE20231958A1 (en) 2015-07-30 2023-12-06 Macrogenics Inc BINDING MOLECULES TO PD-1 AND METHODS OF USE THEREOF
WO2017023972A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10329309B2 (en) 2015-08-03 2019-06-25 Samumed, Llc 3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017023988A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10392383B2 (en) 2015-08-03 2019-08-27 Samumed, Llc 3-(1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10519169B2 (en) 2015-08-03 2019-12-31 Samumed, Llc 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017024004A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10231956B2 (en) 2015-08-03 2019-03-19 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
AU2015406253B2 (en) 2015-08-20 2021-02-25 Js Innopharm (Shanghai) Ltd. Pyrazolo fused heterocyclic compounds as ERK inhibitors
WO2017058915A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
MA52119A (en) 2015-10-19 2018-08-29 Ncyte Corp HETEROCYCLIC COMPOUNDS USED AS IMMUNOMODULATORS
EP3365335B1 (en) 2015-10-23 2024-02-14 Array Biopharma, Inc. 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases
SG11201804152RA (en) 2015-11-19 2018-06-28 Incyte Corp Heterocyclic compounds as immunomodulators
TW201726623A (en) 2015-12-17 2017-08-01 英塞特公司 Heterocyclic compounds as immunomodulators
ES2844374T3 (en) 2015-12-22 2021-07-22 Incyte Corp Heterocyclic compounds as immunomodulators
EP3452476B1 (en) 2016-05-06 2021-12-15 Incyte Corporation Heterocyclic compounds as immunomodulators
TW201808902A (en) 2016-05-26 2018-03-16 美商英塞特公司 Heterocyclic compounds as immunomodulators
ES2927984T3 (en) 2016-06-20 2022-11-14 Incyte Corp Heterocyclic compounds as immunomodulators
WO2017223414A1 (en) 2016-06-24 2017-12-28 Incyte Corporation HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS
ES2930092T3 (en) 2016-07-14 2022-12-07 Incyte Corp Heterocyclic compounds as immunomodulators
ES2941716T3 (en) 2016-08-29 2023-05-25 Incyte Corp Heterocyclic compounds as immunomodulators
WO2018041091A1 (en) 2016-08-30 2018-03-08 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication, application methods and uses thereof
US20180072718A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine compounds and uses thereof
BR112019005305A2 (en) 2016-10-05 2019-07-02 Zeno Royalties & Milestones Llc spirocyclic compounds
KR101755556B1 (en) 2016-11-18 2017-07-07 주식회사 케마스 Pharmaceutical composition for prevention or treatment of brain cancer comprising polymorphic form of tetraarsenic oxide and preparation method thereof
KR101834366B1 (en) 2016-11-21 2018-03-05 주식회사 케마스 Pharmaceutical composition for prevention or treatment of breast cancer comprising polymorphic form of tetraarsenic oxide and preparation method thereof
KR101844049B1 (en) 2016-12-05 2018-03-30 주식회사 케마스 Pharmaceutical composition for prevention or treatment of liver cancer comprising polymorphic form of tetraarsenic oxide
KR101844050B1 (en) 2016-12-09 2018-05-14 주식회사 케마스 Pharmaceutical composition for prevention or treatment of cancer comprising polymorphic form of tetraarsenic oxide
US20180179202A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018119263A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds derivatives as pd-l1 internalization inducers
US20180179179A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
EP3558985B1 (en) 2016-12-22 2022-09-07 Incyte Corporation Benzooxazole derivatives as immunomodulators
MX2019007651A (en) 2016-12-22 2020-02-07 Incyte Corp Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers.
ES2874756T3 (en) 2016-12-22 2021-11-05 Incyte Corp Triazolo [1,5-A] pyridine derivatives as immunomodulators
AR111960A1 (en) 2017-05-26 2019-09-04 Incyte Corp CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION
WO2018234354A1 (en) 2017-06-20 2018-12-27 Grünenthal GmbH Novel substituted 3-indole and 3-indazole compounds as phosphodiesterase inhibitors
WO2019037640A1 (en) 2017-08-22 2019-02-28 Js Innopharm (Shanghai) Ltd Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
US10793551B2 (en) 2017-10-19 2020-10-06 Effector Therapeutics Inc. Benzimidazole-indole inhibitors of Mnk1 and Mnk2
ES2908283T3 (en) 2017-12-02 2022-04-28 Galapagos Nv New compounds and pharmaceutical compositions thereof for the treatment of diseases
MX2020010321A (en) 2018-03-30 2021-01-08 Incyte Corp Heterocyclic compounds as immunomodulators.
US11466004B2 (en) 2018-05-04 2022-10-11 Incyte Corporation Solid forms of an FGFR inhibitor and processes for preparing the same
MA52493A (en) 2018-05-04 2021-03-10 Incyte Corp FGFR INHIBITOR SALTS
DK3790877T3 (en) 2018-05-11 2023-04-24 Incyte Corp TETRAHYDRO-IMIDAZO[4,5-C]PYRIDINE DERIVATIVES AS PD-L1 IMMUNE MODULATORS
SG11202101151SA (en) 2018-08-14 2021-03-30 Osteoqc Inc Pyrrolo - dipyridine compounds
WO2020049017A1 (en) 2018-09-07 2020-03-12 Merck Patent Gmbh 5-morpholin-4-yl-pyrazolo[4,3-b]pyridine derivatives
WO2020131627A1 (en) 2018-12-19 2020-06-25 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
JP2022515197A (en) 2018-12-19 2022-02-17 アレイ バイオファーマ インコーポレイテッド 7-((3,5-dimethoxyphenyl) amino) quinoxaline derivative as an FGFR inhibitor for treating cancer
JP7148802B2 (en) 2019-01-25 2022-10-06 富士通株式会社 Analysis program, analysis method and analysis device
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US20210094935A1 (en) 2019-10-01 2021-04-01 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CA3157361A1 (en) 2019-10-14 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
JP2023505258A (en) 2019-12-04 2023-02-08 インサイト・コーポレイション Tricyclic heterocycles as FGFR inhibitors
BR112022010664A2 (en) 2019-12-04 2022-08-16 Incyte Corp DERIVATIVES OF A FGFR INHIBITOR
US20210214366A1 (en) 2020-01-15 2021-07-15 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors

Also Published As

Publication number Publication date
TW201920173A (en) 2019-06-01
CN105263931A (en) 2016-01-20
EP3318564B1 (en) 2021-07-28
EP2986610B9 (en) 2018-10-17
CA3130452C (en) 2023-10-31
WO2014172644A3 (en) 2014-12-18
CA2909207A1 (en) 2014-10-23
EP2986610A2 (en) 2016-02-24
AU2014253798B2 (en) 2018-08-09
TW201512195A (en) 2015-04-01
EA202090516A2 (en) 2020-06-30
US20140315902A1 (en) 2014-10-23
CA3130452A1 (en) 2014-10-23
HRP20180365T2 (en) 2019-06-28
IL262038B (en) 2022-06-01
CN105263931B (en) 2019-01-25
ME03015B (en) 2018-10-20
BR112015026307B1 (en) 2022-03-22
US11530214B2 (en) 2022-12-20
JP6698799B2 (en) 2020-05-27
MX2019010709A (en) 2019-10-21
RS56924B1 (en) 2018-05-31
US9533984B2 (en) 2017-01-03
DK2986610T3 (en) 2018-02-12
LT2986610T (en) 2018-04-10
CL2015003089A1 (en) 2016-04-22
SI2986610T1 (en) 2018-04-30
PH12019502810A1 (en) 2021-01-11
US20200095244A1 (en) 2020-03-26
ECSP15048555A (en) 2017-07-31
HRP20180365T1 (en) 2018-04-20
JP2019069953A (en) 2019-05-09
PE20152033A1 (en) 2016-01-21
AU2020250201B2 (en) 2022-07-07
EP3318564A3 (en) 2018-08-15
EP2986610B1 (en) 2017-12-27
EA035095B1 (en) 2020-04-27
NZ752422A (en) 2020-09-25
HK1255159A1 (en) 2019-08-09
AU2018208772A1 (en) 2018-08-16
IL241982B (en) 2021-02-28
PH12015502383A1 (en) 2016-02-22
CN109776525B (en) 2022-01-21
KR20210079398A (en) 2021-06-29
NO3087075T3 (en) 2018-07-14
RS56924B9 (en) 2019-09-30
EA201592005A1 (en) 2016-02-29
IL262038A (en) 2018-11-29
HK1221462A1 (en) 2017-06-02
DK2986610T5 (en) 2018-12-10
AR096097A1 (en) 2015-12-09
AU2014253798A1 (en) 2015-10-29
MY181497A (en) 2020-12-23
MX2015014683A (en) 2016-07-05
CR20150578A (en) 2016-02-29
UA120087C2 (en) 2019-10-10
US20190062327A1 (en) 2019-02-28
CN109912594A (en) 2019-06-21
EA202090516A3 (en) 2020-10-30
US20210395246A1 (en) 2021-12-23
AU2020250201A1 (en) 2020-11-05
ES2657451T9 (en) 2018-12-11
TWI715901B (en) 2021-01-11
AU2014253798C1 (en) 2019-02-07
HUE036571T2 (en) 2018-07-30
KR102269032B1 (en) 2021-06-24
PL2986610T4 (en) 2019-06-28
US10947230B2 (en) 2021-03-16
AU2018208772B2 (en) 2020-07-09
NZ713074A (en) 2020-09-25
SG11201508328PA (en) 2015-11-27
JP2020128396A (en) 2020-08-27
CY1120556T1 (en) 2019-07-10
KR20150143707A (en) 2015-12-23
CN109776525A (en) 2019-05-21
WO2014172644A2 (en) 2014-10-23
MX367878B (en) 2019-09-10
PL2986610T3 (en) 2018-05-30
JP6903790B2 (en) 2021-07-14
ES2893725T3 (en) 2022-02-09
ES2657451T3 (en) 2018-03-05
PT2986610T (en) 2018-03-09
US20170166564A1 (en) 2017-06-15
KR102469849B1 (en) 2022-11-23
BR112015026307A2 (en) 2017-10-10
US10040790B2 (en) 2018-08-07
US10450313B2 (en) 2019-10-22
CA2909207C (en) 2021-11-02
JP2016518372A (en) 2016-06-23
EP3318564A2 (en) 2018-05-09
JP6449244B2 (en) 2019-01-09
TWI649318B (en) 2019-02-01

Similar Documents

Publication Publication Date Title
HRP20180365T2 (en) Bicyclic heterocycles as fgfr inhibitors
HK1246794A1 (en) Bicyclic heterocycles as fgfr inhibitors
ZA202001242B (en) Tricyclic heterocycles as bet protein inhibitors
IL279682A (en) Benzoquinolone inhibitors of vmat2
HK1223617A1 (en) Tricyclic heterocycles as bet protein inhibitors bet
EP2970340A4 (en) Beta-lactamase inhibitors
EP2943204A4 (en) Beta-lactamase inhibitors
GB201314578D0 (en) Bicyclic inhibitors
HRP20170247T1 (en) Bicyclic compounds
HK1221645A1 (en) Benzoquinolone inhibitors of vmat2 vmat2
HK1213885A1 (en) Imidazo-triazine derivatives as pde10 inhibitors pde10 -
EP2968324A4 (en) Substituted pyridizinone derivatives as pde10 inhibitors